Research Poster Presentations – Session V

Wednesday, May 20, 2015
8:30AM-2:45PM

Poster Author Discussion Hour:
12:45PM-1:45PM

Research Poster Presentations – Session V includes the following topics

<table>
<thead>
<tr>
<th>PHS – HEALTH SERVICES</th>
<th>PND – NEUROLOGICAL DISORDERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rows A-J</td>
<td>Rows J-N</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PSY – SYSTEMIC DISORDERS/CONDITIONS</th>
<th>Rows N-X</th>
</tr>
</thead>
</table>

A1  Location of the poster in the poster hall – please refer to last page for a floor plan

pgA10  Location of the abstract as published in Value in Health Volume 18, Issue 3
PHS1 A1 pgA247 MEDICATION UTILIZATION IN INCIDENT ADVERSE DRUG REACTIONS OF CANCER CHEMOTHERAPY - A PHARMACIST PERSPECTIVE
Guntupalli L, chalapathi institute of pharmaceutical sciences, guntur, AA, India

PHS2 A2 pgA247 SENTINEL SITE ACTIVE SURVEILLANCE OF THE SAFETY OF FIRST-LINE ANTIRETROVIRAL MEDICINES IN NAMIBIA
Mann M1, Mengistu A2, Gaeseb J3, Sagwa E4, Mazibuko G5, Garrison LP1, Stergachis A1, University of Washington, Seattle, WA, USA, 2Therapeutics Information and Pharmacovigilance Centre Namibia, Windhoek, Namibia, 3Ministry of Health and Social Services Namibia, Windhoek, Namibia, 4Management Sciences for Health, Windhoek, Namibia

PHS3 A3 pgA248 CACHEXIA & DEBILITY IN HOSPITALIZED CHILDREN WITH COMPLEX CHRONIC CONDITIONS
Van Doren BA1, Roy D1, Noone J2, Blanchette CM1, Arthur S2, University of North Carolina, Charlotte, Charlotte, NC, USA, 2University of North Carolina at Charlotte, Charlotte, NC, USA

PHS4 A4 pgA248 PATIENT AND HOSPITAL-LEVEL FACTORS ASSOCIATED WITH INPATIENT MORTALITY OF STROKE PATIENTS
Sharma M1, Ferries EA, Yucel A, Johnson ML, Aparasu R, University of Houston, Houston, TX, USA

PHS5 A5 pgA248 CONTEXTUAL ANALYSIS OF DETERMINANTS OF LATE DIAGNOSIS OF HEPATITIS C VIRUS INFECTION IN MEDICARE PATIENTS
Chirikov VV1, Shaya FT1, Howell CD2, University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Howard University College of Medicine, Washington, MD, USA

PHS6 A6 pgA248 RISKS OF FRACTURES IN VITILIGO PATIENTS TREATED WITH PHOTOTHERAPY
Li C1, Lo P2, Huang W3, Wen Y1, Tsai Y4, Tsai T5, National Taiwan University College of Medicine, Taipei, Taiwan, 2National Yang Ming University, Taipei, Taiwan, 3Chang Gung University, Taoyuan, Taiwan, 4National Taiwan University Hospital, Taipei, Taiwan

PHS7 A7 pgA248 REMOTE MONITORING STRATEGIES FOR PATIENTS WITH STABLE HEART FAILURE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Pandor A1, Gomersall T, Stevens JW, Wong R, The University of Sheffield, Sheffield, UK

PHS8 A8 pgA248 PERFORMANCE OF TWO WORLD HEALTH ORGANIZATION DENGUE CLASSIFICATIONS IN A PEDIATRIC COHORT FROM COLOMBIA
Pinzón-Redondo H1, Paternina-Caicedo A2, Alvis-Guzman N2, Diaz-Quijano F3, Zarate-Vergara A4, Barrios-Redondo K5, De la Hoz-Restrepo F6, Hospital Infantil Napoleón Franco Pareja, Cartagena, Colombia, 2Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 3Universidad de Sao Pablo. Depatamento de Salud Pública, Sao Pablo, Brazil, 4Hospital Infantil Napoleón Franco Pareja, Cartagena, Colombia, 5Instituto Nacional de Salud, BOGOTA D.C., Colombia

PHS9 A9 pgA249 IS PHARMACEUTICAL CARE EFFECTIVE FOR IMPROVING BLOOD PRESSURE CONTROL AND MEDICATION ADHERENCE AMONG HYPERTENSIVE PATIENTS? A REVIEW
Eziyi A1, Adunlin G, Florida A & M University, Tallahassee, FL, USA

PHS10 A10 pgA249 EFFECTS OF SOCIAL NETWORKS ON PATIENT ADHERENCE TO PRESCRIBED TREATMENT FOR SERIOUS MENTAL ILLNESS: A SYSTEMATIC REVIEW
LyttleNguessan CJ1, Campbell ES, Florida A&M University, Tallahassee, FL, USA

PHS11 A11 pgA249 PREDICTORS OF ALLOPURINOL ADHERENCE IN PATIENTS WITH GOUT
Singh Ja1, UAB SCHOOL OF MEDICINE, Birmingham, AL, USA

PHS12 A12 pgA249 COMPARISON OF THE IMPACT OF HUMAN VERSUS ANALOGUE INSULINS ON GLYCOSYLATED HEMOGLOBIN IN A POPULATION WITH DIABETES MELLITUS COLOMBIA
Machado J1, Medina D, Universidad Tecnológica de Pereira, Pereira, Colombia

PHS13 A13 pgA249 MANAGEMENT OF TUBEROUS SCLEROSIS COMPLEX IN ENGLAND: INSIGHTS INTO REAL-WORLD CLINICAL PRACTICE
Kingswood C1, Dew R2, Gray E3, (On behalf of the TSC clinic network) The Royal Sussex County Hospital, Brighton, UK, 2pH Associates Ltd, Marlow, UK, 3Novartis Pharmaceuticals UK Ltd, Frimley, UK

PHS14 A14 pgA249 PREDICTORS OF CIGARETTE SMOKING IN THREE ASIAN COUNTRIES: CHINA INDIA AND TAIWAN
Almogbel Y1, Abughosh S, Essien EJ, Sansgiry SS, University of Houston, Houston, TX, USA

PHS15 A15 pgA250 ASSESSMENT OF AWARENESS REGARDING HEPATITIS B AMONG WOMEN IN ABBOTTABAD, KPK PAKISTAN
Azhar SA1, Hassali AA2, Sana SS1, Faiza FH1, Zainab ZB1, Sundas SA1, Mahrukh MA1, Noman NH2, Fahad FS2, Izhar IH1, COMSATS Institute of Information Technology, Abbottabad, Pakistan, 2Universiti Sains Malaysia,
Health Services - Cost Studies

**PHS16** A16 pgA250 PREVALENCE AND BURDEN OF ALPHA-1 ANTITRYPSIN DEFICIENCY AMONG HOSPITALIZED COPD PATIENTS IN THE US
Blanchette CM¹, Noone J¹, Roy D², Van Dorenb A³, Zacherle E¹, Howden R³,¹University of North Carolina at Charlotte, Charlotte, NC, USA, ²University of North Carolina, Charlotte, Charlotte, NC, USA

**PHS17** A17 pgA250 RACIAL DISPARITIES IN TOTAL ANKLE ARTHROPLASTY UTILIZATION AND OUTCOMES
Singh Ja, Ramchandran R, UAB SCHOOL OF MEDICINE, Birmingham, AL, USA

**PHS18** A18 pgA250 PREVALENCE AND BURDEN OF ANKLE INJURIES IN NORTH CAROLINA EMERGENCY DEPARTMENTS
Shah S, Blanchette CM, Noone J, Wikstrom EA, University of North Carolina at Charlotte, Charlotte, NC, USA

**PHS19** A19 pgA250 NATIONAL TRENDS AND CHARACTERISTICS OF PSYCHIATRIC ADMISSIONS IN US EMERGENCY DEPARTMENTS: 2006-2011
Vohra R, Madhavan SS, Sambamoorthi U, West Virginia University, Morgantown, WV, USA

**PHS20** A20 pgA250 BURDEN OF DISEASE OF HEPATITIS C IN COLOMBIA
Alvis-Guzman N¹, Romero M², De la Hoz-Restrepo F³, Universidade de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, ²Fundación Salutia, Bogotá D.C., Colombia, ³INSTITUTO NACIONAL DE SALUD, Bogotá, Colombia

**PHS21** A21 pgA251 EXAMINING RISK FACTORS AND PREDICTING READMISSIONS IN COPD PATIENTS
Sickler A, Wang QC, Chawla R, Nimig S, Independence Blue Cross, Philadelphia, PA, USA

**PHS22** B1 pgA251 TREATMENT FOR SUBSTANCE USE AND IMPLICATIONS FOR MORTALITY IN ELDERLY PROSTATE CANCER PATIENTS
Chhatre S, Malkowicz SB, Metzer DS, Jayadavappa R, University of Pennsylvania, Philadelphia, PA, USA

**PHS23** B2 pgA251 RELATION BETWEEN HEALTH INSURANCE COVERAGE AND OUTCOMES AMONG WOMEN WITH BREAST CANCER IN FLORIDA
Tawk RH¹, Ali A¹, Adunlin G², Xiao H², Florida A & M University, Tallahassee, FL, USA, “Florida A & M University, Tallahassee, FL, USA

**PHS24** B3 pgA251 PERIPHERAL ARTERIAL DISEASE MANAGEMENT PROGRAM: SCREENING-RISK FACTOR MANAGEMENT PROGRAM AND FINANCIAL RETURN ON INVESTMENT
Luque A¹, Junqueira Junior SM², Cabra HA², Andrade PC², Oliveira FM¹, Johnson & Johnson Medical Brazil, São Paulo, Brazil, ²Johnson & Johnson Medical Brazil, Sao Paulo, Brazil, ³Johnson & Johnson Medical, Mexico, D.F., Mexico

**PHS25** B4 pgA251 ECONOMIC BURDEN OF ADVERSE EVENTS ASSOCIATED WITH FIRST LINE METASTATIC RENAL CELL CARCINOMA (MRCC) TREATMENT IN PUBLIC AND PRIVATE BRAZILIAN PERSPECTIVE
Ferreira CN, Santana CF, Rufino CS, Pfizer Brasil, São Paulo, Brazil

**PHS26** B5 pgA252 IMPACT OF NON-MEDICAL SWITCHING ON HEALTHCARE COSTS: A CLAIMS DATABASE ANALYSIS
Liu Y¹, Skup M², Lin J³, Chao J²,¹University of Missouri–Kansas City, Kansas City, MO, USA, ²AbbVie Inc., North Chicago, IL, USA, ³Novosys Health, Green Brook, NJ, USA

**PHS27** B6 pgA252 INCREASED HEALTHCARE UTILIZATION ASSOCIATED WITH OBESITY
Hoshen MB, Balicer R, Clalit Health Services, Tel Aviv, Israel

**PHS28** B7 pgA252 COST OF IMPLEMENTING A PEDIATRIC NEUROCRIITICAL CARE CENTER
Buchanan P¹, Howard S¹, Zhang Z², Buell C¹, Pearson L¹, Huetsch M¹, Gill J², Pineda J³, Saint Louis University, Saint Louis, MO, USA, ²Washington University, Saint Louis, MO, USA

**PHS29** B8 pgA252 DIFFERENCES IN THE TOTAL HEALTHCARE COSTS DURING THE YEAR OF DIAGNOSIS BETWEEN APPALACHIAN AND A NATIONAL COHORT OF ELDERLY WOMEN WITH BREAST CANCER: AN APPLICATION OF DECOMPOSITION TECHNIQUE
Vyas A¹, Madhavan SS², Sambamoorthi U³, Pan X³, Regier M¹, Hazard H¹, Rutgers University, Piscataway, NJ, USA, ²West Virginia University, Morgantown, WV, USA, ³Evidera LLC, Lexington, MA, USA

**PHS30** B9 pgA252 ASSESSING THE FULL BURDEN OF CARE FOR AGITATION IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR I DISORDER
Margolis MK¹, Bapat B¹, Blume S¹, Cicero S², Gandhi SK³, Evidera, Bethesda, MD, USA, “Evidera, Lexington, MA, USA, “TEVA Pharmaceuticals, Frazer, PA, USA

**PHS31** B10 pgA252 COMMON REASONS FOR AND ASSOCIATED COSTS OF PEDIATRIC INPATIENT ADMISSIONS IN THE UNITED STATES
Meyers J, Candrilli S, RTI Health Solutions, Research Triangle Park, NC, USA

**PHS32** B11 pgA253 DIRECT MEDICAL COST OF COMPLICATIONS IN PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION NVAF AT A PRIVATE HOSPITAL IN VENEZUELA
Fernandez Y¹, Chiquinquira K², Garrido Lecca S³, University Central de Venezuela Facultad de Medicina Escuela de Salud Publica, Caracas, Venezuela, ²Unesar Clinica Santa Sofia, Caracas, Venezuela, ³Bristol-Myers
DIRECT COSTS OF HEALTHCARE OF MULTIPLE SCLEROSIS, THE CASE OF A HEALTH MAINTAINANCE ORGANIZATION IN COLOMBIA

Muñoz-Galindo IM¹, Moreno JA¹, Guarin NE¹, Díaz JA², Arevalo HO¹,¹Salud Total EPS, Bogotá D.C., Colombia, ²Universidad Nacional de Colombia, Bogotá D.C., Colombia

INCREMENTAL BURDEN OF GROUP 3 PULMONARY HYPERTENSION PATIENTS TO U.S. PAYER

Heresi GA¹, Joish VN², Platt D³, Abad M⁴, Kamalakar R⁵, Teal S⁶, Satler C⁷, Department of Pulmonary and Critical Care Medicine, Cleveland, OH, USA, ¹Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, ²BAYER HEALTHCARE PHARMACEUTICALS, WHIPPANY, NJ, USA, ³Bayer Pharma AG, Berlin, Germany

HOSPITALIZATION COSTS DUE TO SEVERE ACUTE RESPIRATORY INFECTION (SARI) IN THREE CENTRAL AMERICAN COUNTRIES

Alvis-Guzmán N⁸, Marin-Correa C⁹, Castañeda-Orjuela C¹⁰, Sanchez-Ruiz C¹¹, Carrasquilla-Sotomayor M¹², Sanchez F¹³, Mena R¹⁴, Mejia H¹⁵, Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, ¹Instituto Nacional de Salud, BOGOTA D.C., Colombia, ²TEPHINET, Bogota D.C., Colombia, ³Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, ⁴Universidad Autónoma de Nicaragua, Managua, Nicaragua, ⁵Hospital General San Juan de Dios, San Lucas Sacatepéquez, Guatemala, ⁶Secretaría de Salud, Tegucigalpa, Honduras

RACIAL VARIATION IN THE CLINICAL AND ECONOMIC BURDEN OF SKELETAL-RELATED EVENTS AMONG ELDERLY MEN WITH STAGE IV METASTATIC PROSTATE CANCER

Jayasekera J¹, Onukwugha E¹, Bikov K¹, Hussain A¹,¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Maryland School of Medicine, Baltimore, MD, USA

COST OF COLORECTAL CANCER IN VIETNAM

Nguyen T, Phan T, Nguyen TT, University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam

DIRECT MEDICAL COSTS ASSOCIATED WITH CLINICAL AND HEALTH CHARACTERISTICS IN VISUALLY IMPAIRED INDIVIDUALS IN SINGAPORE

Luo N¹, Wang X¹, Finkelstein EA², Lamoureux E³, Aung T⁴, Wong TY⁴, Ang M⁴,¹National University of Singapore, Singapore, Singapore, ²Duke-NUS Graduate Medical School, Singapore, Singapore, ³Duke, Singapore, Singapore, ⁴Singapore National Eye Center, Singapore, Singapore

ECONOMIC BURDEN OF VACCINE-PREVENTABLE DISEASES AMONG THE ELDERLY IN TAIWAN

Lu W¹, Yang HK¹, Chen L¹, Hsiao F¹,¹National Taiwan University, Taipei, Taiwan, ²Merck & Co., Inc., West Point, PA, USA, ³Taipei Veterans General Hospital, Taipei, Taiwan

DIRECT COSTS OF HEALTHCARE FOR BREAST CANCER, THE CASE OF A HEALTH MAINTAINANCE ORGANIZATION IN COLOMBIA

Moreno JA¹, Muñoz-Galindo IM¹, Guarín NE¹, Díaz JA², Arevalo HO¹,¹Salud Total EPS, Bogotá D.C., Colombia, ²Universidad Nacional de Colombia, Bogotá D.C., Colombia

CLINICAL AND ECONOMIC ANALYSIS OF SIMPLE CONTACT DERMATITIS DUE TO URINARY INCONTINENCE AND PRESSURE ULCERS OF IMMOBILIZED PATIENTS WITH URINARY INCONTINENCE

Vorobiev A, Vorobiev P, Krasnova L, Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia

ECONOMIC BURDEN OF COLORECTAL CANCER IN VIETNAM: FROM HEALTHCARE PAYERS’ PERSPECTIVE

Phan T, Hoang B, Nguyen TT, University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam

MEDICAL CARE COSTS OF CHIKUNGUNYA VIRUS INFECTION IN A PEDIATRIC POPULATION IN COLOMBIA

Castañeda-Orjuela C¹, Díaz-Jiménez D¹, Rodriguez-Castillo L¹, Paternina-Caicedo A², Pinzón-Redondo H², Alvis-Guzman N³, de la Hoz-Restrepo F¹,¹Instituto Nacional de Salud, BOGOTA D.C., Colombia, ²Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, ³Hospital Infantil Napoleón Franco Pareja, Cartagena., Colombia

DIRECT COST OF HYPOTHYROIDISM AND ITS COMPLICATIONS IN UKRAINE

Vadziuk I, Ivan Horbachovskyy Ternopil State Medical University, Ternopil, Ukraine

CLINICAL AND ECONOMIC IMPACT OF THE INTRODUCTION OF THE VACCINE AGAINST MENINGOCOCCAL MENINGITIS C IN CHILDREN AGED 0-4 YEARS IN BRAZIL

Andrade TR, Sansone D, Etto H, Decimoni TC, Araujo GT, Fonseca M, AxiaBio, São Paulo, Brazil

PATIENT RECALL FOLLOWING BREAST CANCER SCREENING MAMMOGRAPHY AMONG MEDICAID PATIENTS BY PATIENT RACE

Bonafede MM¹, Miller JD¹, Huang A², Troeger KA³, Fajardo L⁴, ¹Truven Health Analytics, Cambridge, MA, USA, ²Truven Health Analytics, Bethesda, MD, USA, ³Hologic, Inc., Marlborough, MA, USA, ⁴University of Iowa, Iowa City, IA, USA

DIRECT AND INDIRECT COSTS TO EMPLOYERS OF RECALL FOLLOWING SCREENING
MAMMOGRAPHY AMONG FEMALE EMPLOYEES IN THE US

Bonafele MM, Miller JD, Huang A, Troeger KA, Fajardo L, Truven Health Analytics, Cambridge, MA, USA, 1Truven Health Analytics, Bethesda, MD, USA, 2Hologic, Inc., Marlborough, MA, USA, 3University of Iowa, Iowa City, IA, USA

PFS49 C6 pgA255 NOVEL APPROACH TO CATEGORIZING COSTS OF PATIENTS EXPERIENCING SEIZURES

Williams DV, Wix DA, Milliman, Windsor, CT, USA

PFS50 C7 pgA255 ESTIMATING THE COST OF PNEUMONIA CASES ADMITTED AT THE INTERNAL MEDICINE WARDS OF A TERTIARY GOVERNMENT HOSPITAL IN THE PHILIPPINES

Rivera AS, University of the Philippines Manila, Manila, Philippines

PFS51 C8 pgA256 DIRECT COSTS COMPARISON OF MEDICAL CARE BEFORE AND AFTER HEART FAILURE HOSPITALIZATION IN A MEDICARE POPULATION

Kilgore M, Patel H, Sharma P, Maya J, Kiellhorn A, University of Alabama at Birmingham, Birmingham, AL, USA, 2Amgen, Thousand Oaks, CA, USA

PFS52 C9 pgA256 COST OF A PHARMACIST-LED PNEUMONIA EDUCATION AND IMMUNIZATION PROGRAM FOR OLDER PHILADELPHIANS

Alcusky MJ, Cannon-Dang E, Steele D, Schafer JJ, DeSimone Jr. JA, Pizzi LT, Thomas Jefferson University, Philadelphia, PA, USA

PFS54 C10 pgA256 AN ACCESSIBLE APPROACH TO ESTIMATE THE DIRECT MEDICAL COSTS OF TYPE 2 DIABETES MELLITUS FOR THE BRAZILIAN NATIONAL HEALTH SYSTEM

Aquino CM, Lima RC, Marino MG, Sousa IM, Cesse EA, Bezerra AF, Federal University of Pernambuco, Recife, Brazil, 2Federal University of Pernambuco, RECIFE, Brazil, 3Oswaldo Cruz Foundation - Fiocruz, Recife, Brazil

PFS55 C11 pgA256 COST ANALYSIS OF PATIENTS WITH ACUTE CORONARY EVENT IN A COMMERCIAL INSURANCE COMPANY IN COLOMBIA — SALUDCOOP — IN 2013

Romero M, Torres A, Grosso G, Urrutia C, Salutia Foundation, Bogota, Colombia, 2Salutia’s Foundation Research center in economy, management and health technologies., Bogota, Colombia, 3Group SaludCoop, Bogota, Colombia

PFS56 C12 pgA256 IMPACT OF CLINICAL PHARMACIST INTERVENTIONS ON THE PRESCRIBING HABIT AND COST SAVING

Alkhalaf MS, Dammam Medical Complex, Dammam, Saudi Arabia

PFS59 C13 pgA257 COST OF REPORTING POSSIBLE ADVERSE DRUG REACTIONS IN MEDICAL OUTPATIENTS USING A TELEPHONIC INTERACTIVE VOICE RESPONSE SYSTEM

Mahida SR, Seoane E, Klinger E, Salazar A, HERQL, Medoff J, Amato M, Dykes PC, Haas J, Bates D, Schiff G, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Brigham and Women's Hospital, Boston, MA, USA

PFS60 C14 pgA257 COST OF CANCER TREATMENT IN BRAZIL AND ITS DETERMINANTS: 2000-2003

Cherchiglia ML, Perelman J, Pereira J, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2Universidade NOVA de Lisboa, Lisboa, Portugal

PFS61 C15 pgA257 USING BIG DATA FOR AN ECONOMIC EVALUATION OF REDUCING THE INAPPROPRIATE PRESCRIBING OF ATYPICAL ANTIPSYCHOTICS AMONG DEMENTIA PATIENTS


PFS62 C16 pgA257 COST-EFFECTIVENESS OF A BEHAVIORAL PSYCHOSOCIAL TREATMENT INTEGRATED ACROSS HOME AND SCHOOL FOR PEDIATRIC ADHD-INATTENTIVE TYPE


PFS63 D1 pgA258 ECONOMIC EVALUATION OF A RANDOMIZED CONTROLLED TRIAL OF PHARMACIST-SUPERVIZED PATIENT SELF-TESTING OF WARFARIN THERAPY

Gallagher J, University College Cork, Cork, Ireland

PFS64 D2 pgA258 COST-EFFECTIVENESS OF BREAST CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM IN THE UNITED STATES


PFS65 D3 pgA258 COST EFFECTIVENESS OF GROUP-BASED PARENTING PROGRAMS AND BIBLIOTHERAPY FOR PARENTS OF CHILDREN AT RISK OF DEVELOPING CONDUCT DISORDER: A MULTICENTER RANDOMIZED CONTROLLED TRIAL

Sampaio F, Enebrink P, Mihalopoulos C, Feldman I, Uppsala University, Uppsala, Sweden, 2Karolinska Institute, Stockholm, Sweden, 3Deakin University, Melbourne, Australia

PFS66 D4 pgA258 COST-UTILITY ASSESSMENT OF HEMODIALYSIS VERSUS DIALYSIS PERITONEAL, AS TREATMENT
OUT-OF-POCKET MEDICAL COSTS FOR PARENTS WITH CHILDREN WITH DOWN SYNDROME IN THE UNITED STATES
Kageleire A1, Samuelson D2, Duh MS2, Lefebvre P2, DerSarkissian M4, Campbell JY3, Skotko BG1, Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Boston, MA, USA, 3Groupe d'analyse, Itée, Montreal, QC, Canada, 4Analysis Group, Los Angeles, CA, USA, 5Harvard University, Cambridge, MA, USA, 6Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

EXPECTED COSTS AND HEALTH OUTCOMES FOR A COHORT OF ALBERTANS DIAGNOSED WITH HEPATITIS C
Thanh NX1, Jacobs P1, Waye A1, Tyrrell DL1, Misurski D3, Institute of Health Economics, Edmonton, AB, Canada, 1University of Alberta, Edmonton, AB, Canada, 2Abvbiue, Chicago, IL, USA

ESTIMATING HEALTHCARE RESOURCE USE ASSOCIATED WITH THE TREATMENT OF METASTATIC MELANOMA IN EIGHT COUNTRIES
McKendrick J1, Gijsen M1, Quinn C1, Zhao Z1, Barber BL4, PRMA Consulting, Fleet, UK, 2Amgen Inc, Thousand Oaks, CA, USA

ASSOCIATION OF CHANGE IN FORCED VITAL CAPACITY WITH HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH NEWLY DIAGNOSED IDIOPATHIC PULMONARY FIBROSIS
Reichmann WM1, Yu Y2, Macaulay D3, Nathan SD3, Analysis Group, Inc., Boston, MA, USA, 2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 3Analysis Group, Inc., New York, MA, USA, 4Inova Heart and Vascular Institute, Falls Church, VA, USA

BURDEN OF MELANOMA AMONG ADULTS ENROLLED IN MEDICAID PROGRAM
Shah R1, Khanna R, Pace P, Banahan III B, University of Mississippi, University, MS, USA

EXPANSION OF CURRENT HPV VACCINATION GUIDELINES TO INCLUDE MEN WHO HAVE SEX WITH MEN WHO ARE 27 YEARS OR OLDER – A VALUE OF INFORMATION ANALYSIS
Deshmukh AA1, Cantor SB1, Chiao EY2, Nyitray AG2, Das P1, Chhatwal J1, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2Baylor College of Medicine, Houston, TX, USA, 3The University of Texas School of Public Health, Houston, TX, USA

HEALTH SERVICES - Patient-Reported Outcomes & Patient Preference Studies

IMPACT OF EMAIL REFILL REMINDERS ON MEDICATION ADHERENCE AMONG PATIENTS WITH CHRONIC DISEASES IN A RETAIL COMMUNITY PHARMACY
Taitel MS, Mu Y, Lou Y, Cannon A, Walgreen Co., Deerfield, IL, USA

IMPACT OF APPOINTMENT-BASED MEDICATION SYNCHRONIZATION ON EXISTING USERS OF CHRONIC MEDICATIONS
Holdford DA, Saxena K, Virginia Commonwealth University, Richmond, VA, USA

EXAMINING THE IMPACT OF A HYBRID CLINICAL PHARMACY PRACTICE MODEL ON MEDICATION ADHERENCE IN PATIENTS WITH METABOLIC SYNDROME
Pinto S, Hastings TJ, Bechtol R, Vaidya V, Khuder S, University of Toledo, Toledo, OH, USA

THREE METHODS TO ASSESS ADHERENCE TO HIV ANTIRETROVIRAL TREATMENT IN A CHILEAN HEALTHCARE SETTING
San Martin B1, Lopez M4, Cordova P2, Fernandez P4, Morales F5, Villa L4, Hospital Chiloe, Chiloe, Chile, 2Facultad de Farmacia, Universidad de Concepcion, Concepcion, Chile

PHARMACOTHERAPY OPTIMIZATION PLAN FOR PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) AND HYPERTENSION IN A CHILEAN HEALTHCARE SETTING: IMPACT AND OUTCOMES
Soto A1, Avila X2, Cordova P3, Fernandez P3, Lopez M4, Villa LA3, Morales F5, CESFAM Bicentenario, Arauco, Chile, 2San Vicente Hospital, Arauco, Chile, 3Facultad de Farmacia, Universidad de Concepcion, Concepcion, Chile

DEVELOPMENT AND VALIDATION OF PATIENT DECISION AID yREGARDING ANTIDEPRESSANT MEDICATIONS:y
Al Jumah ka1, Hassali AA2, MOH, Riyadh, Saudi Arabia, 1Universiti Sains Malaysia, Penang, Malaysia

IMPACT OF STRUCTURED PATIENT EDUCATION ON QUALITY OF LIFE OF SOUTH INDIAN DIABETICS
Talla V1, Yellu NR2, Pippalla SR2, Rao V3, Pattnaik S4, Subudhi S3, Budike R1, Pandalaneni A2, Talla Padmavathi College of Pharmacy, Warangal, INDIA, 2UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES, KAKATIYA UNIVERSITY, WARANGAL, India, 3TALLA PDAMAVATHI COLLEGE OF PHARMACY, WARANGAL, India, 4Talla Padmavathi Pharmacy College, Warangal, WARANGAL, INDIA

A VISION ‘BOLT-ON’ ITEM INCREASED THE SENSITIVITY OF EQ-5D IN A CROSS-SECTIONAL HEALTH
PHS81 E3 pgA261 LEAN WORKFLOW CHANGES MAY CONTRIBUTE TO IMPROVED PRIMARY CARE PATIENT SATISFACTION
Chen P, Palo Alto Medical Foundation, Mountain View, CA, USA

PHS82 E4 pgA261 DESCRIPTION OF PATIENTS SATISFACTION OR DISSATISFACTION WITH REFERRAL AND COUNTER REFERRAL PROCESS
Mogere DM, Loum CS, Kaseje D, Great Lakes University of Kisumu, Nairobi, Kenya

PHS83 E5 pgA261 TUBERCULOSIS SCREENING PREFERENCES OF HEALTHCARE WORKERS IN SOUTH AFRICA: A BEST-WORST SCALING STUDY TO ANALYZE VARIATION BY OCCUPATION
O’Hara NN1, Roy L1, O’Hara LM1, Spiegel JM1, Lynd LD1, FitzGerald JM1, Yassi A1, Nophage LE2, Marra CA1, University of British Columbia, Vancouver, BC, Canada, 2University of the Free State, Bloemfontein, South Africa, 3Memorial University, St. John’s, NF, Canada

PHS84 E6 pgA261 SHARED DECISION MAKING DOES NOT IMPROVE ADHERENCE TO PROSTATE CANCER SCREENING: EVIDENCE FROM THE HEALTH INFORMATION NATIONAL TREND SURVEY
Haider MR1, Qureshi Z1, Horner R1, Bennett C1, Khan MM1, University of South Carolina, Columbia, SC, USA, 2University of South Carolina College of Pharmacy, Columbia, SC, USA, 3University of South Carolina, COLUMBIA, SC, USA

PHS85 E7 pgA261 HEALTH RELATED QUALITY OF LIFE AND HEALTH CARE RESOURCE USE BURDEN IN MIGRAINE WITH AND WITHOUT NAUSEA
Flores NM1, Lee LK1, Gajria KS2, Pomerantz D3, Gandhi SK2, Kantar Health, Foster City, CA, USA, 2Teva Pharmaceuticals Inc, Malvern, PA, USA, 3Kantar Health, Horsham, PA, USA

PHS86 E8 pgA262 DO DEPRESSION RATES DIFFER BY CONFLICT ERA AMONG WAR VETERANS?
Adjei Boakye E, Stringer LR, Genreus C, Tobo BB, Buchanan P, Saint Louis University, Saint Louis, MO, USA

PHS87 E9 pgA262 PATIENT REPORTED OUTCOMES REVEAL DISCORDANCE BETWEEN PATIENT AND PHYSICIAN ASSESSMENT OF DISEASE BURDEN IN PATIENTS WITH RHEUMATOID ARTHRITIS
Feinberg BA1, Lal L1, Mujumdar U1, Olson T2, Baraf HS3, Matsumoto AK4, Cardinal Health, Dublin, OH, USA, 2Cardinal Health, Missouri City, TX, USA, 3Cardinal Health, Minneapolis, MN, USA, 4Arthritis and Rheumatism Associates, Wheaton, MD, USA

PHS88 E10 pgA262 FEASIBILITY OF REAL-TIME COLLECTION OF PATIENT REPORTED OUTCOMES AT POINT OF CARE
Feinberg BA1, Baraf HS2, Matsumoto AK2, Olson T2, Mujumdar U1, Cardinal Health, Dublin, OH, USA, “Arthritis and Rheumatism Associates, Wheaton, MD, USA, 2Cardinal Health, Minneapolis, MN, USA

PHS89 E11 pgA262 IMPACT OF PATIENT REPORTED OUTCOMES ON MEDICATION THERAPY MANAGEMENT FOR HIGH-COST SPECIALTY DRUGS
Feinberg BA1, Burruss R1, Traurig T2, Drenning J1, Cardinal Health, Dublin, OH, USA, 2OncoSource Rx, Columbia, MD, USA, 3Cardinal Health, Dallas, TX, USA

PHS90 E12 pgA262 GEOGRAPHIC PATTERNS OF SELF-REPORTED LIFETIME DEPRESSION DIAGNOSIS
Tobo BB, Adjei Boakye E, Buchanan P, Saint Louis University, Saint Louis, MO, USA

PHS91 E13 pgA263 [EVALUATION OF THE QUALITY OF LIFE OF DIABETIC PATIENTS IN MINAS GERAIS STATE, BRAZIL]
Mata AR1, Ferreira Ha1, Alveses J1, Silva MR1, Araujo VE1, Diniz Lm2, Acuicor Fa1, College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2Medical College, Federal University of Minas Gerais, Belo Horizonte, Brazil

HEALTH SERVICES - Health Care Use & Policy Studies

PHS92 E14 pgA263 PREDICTORS OF MAMMOGRAPHY SCREENING AMONG WOMEN AGED 50-74
Nduaguba O, Sudhappali P, Barner J, The University of Texas at Austin, Austin, TX, USA

PHS93 E15 pgA263 DISCUSSION BETWEEN PROVIDERS AND PATIENTS ABOUT PROSTATE SPECIFIC ANTIGEN TESTING IN USA
Mukherjee K1, Segal R2,1, Chicago State University, Chicago, IL, USA, 2University of Florida, Gainesville, IL, USA

PHS94 E16 pgA263 LONG-TERM IMPACT OF A PHARMACIST-LED DIABETES MEDICATION MANAGEMENT PROGRAM ON GLYCEMIC CONTROL
Tran M1, Godley P2, Stock EM3, Rascati KL4, Tabor PA1,5, Scott & White Health Plan, Austin, TX, USA, 2Scott & White Health Plan, Temple, TX, USA, 3Center for Applied Health Research - Central Texas Veterans Health Care System jointly with Baylor Scott & White Health, Temple, TX, USA, 4The University of Texas at Austin, College of Pharmacy, Austin, TX, USA

PHS95 F1 pgA263 ASSESSING A PHYSICIAN VISIT FOR HEPATIC DYSFUNCTION BASED ON DATABASE MERGING CLAIMS AND ANNUAL HEALTH CHECKUP DATA IN JAPAN
PHS96  F2  pgA263  RELATIVE AGE IN CLASS AND ADHD IN SCHOOL CHILDREN – DIAGNOSIS AND MEDICATION PATTERNS – INTRA-ANNUAL AND INTER-ANNUAL DISPARITY
Hoshen MB, Benis A2, Keyes KM1, Zoega H3, Clalit Research Institute, Tel Aviv, Israel, 2Clalit Health Services, Tel Aviv, Israel, 3Columbia University, New York, NY, USA, 4Université de l’Île-de-France, France

PHS97  F3  pgA264  SPECIALTY PHARMACY MEDICATION COMPLIANCE AND PERSISTENCE PROGRAM FOR PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
D’Albini L1, Tian Y2, Raspa S2, Drake W4, 1Accredo, Spring Hill, KS, USA, 2Express Scripts, St. Louis, MO, USA, 3Actelion Pharmaceuticals US, Inc., South San Francisco, CA, USA, 4Actelion Pharmaceuticals, US, Inc., South San Francisco, CA, USA

PHS98  F4  pgA264  DO PHARMACISTS’ BARRIERS—INCLUDING NON-REIMBURSEMENT FOR NON-DISPENSING SERVICES—INFLUENCE THE LEVEL OF ADHERENCE PROMOTION ACTIVITIES FOR PERSONS LIVING WITH HIV?
Kibicho J1, University of Wisconsin-Milwaukee, Milwaukee, WI, USA

PHS99  F5  pgA264  REGISTRY ADOPTED AS PUBLIC POLICY FOR PROPER RISK MANAGEMENT IN CHRONIC KIDNEY DISEASE IN COLOMBIA
Acuna L1, Sanchez P, Soler L, cuenta de alto costo, bogota, Colombia

PHS101  F6  pgA264  HEALTHCARE RESOURCE USE AMONG PATIENTS WITH CONGESTIVE HEART FAILURE IN A LARGE HEALTH ORGANIZATION
Bash LD1, Weitzman D2, Sharon O3, Aviram-Paz M4, Chodick G5, 1Merck and Co., Inc., Rahway, NJ, USA, 2Maccabitech, Maccabi Health Care Services and Tel Aviv University, Tel Aviv, Israel, 3MSD Israel, Hod Hasharon, Israel, 4Tel Aviv University, Tel Aviv, Israel, 5Maccabi Healthcare Services and Tel Aviv University, Tel Aviv, Israel

PHS102  F7  pgA265  WILL U.S. PAYERS CHAMPION BIOSIMILARS?
Malik AN1, Cox J, Keeping K, Decision Resources Group, London, UK

PHS103  F8  pgA265  ARE GENERIC MEDICINES GOOD FOR MY PATIENTS? FINDINGS FROM A QUALITATIVE ASSESSMENT OF PERCEPTIONS AMONG MEDICAL SPECIALISTS IN MALAYSIA
Zhi Yen W1, Hassaí MA2, Alrasheedy AA3, Saleem F4, Mohamad Yahaya AH5, Aljadhhey H6, 1Hospital Teluk Intan, Teluk Intan, Perak, Malaysia, 2Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia, 3Qassim University, Almulyda, Saudi Arabia, 4Universiti Sains Malaysia, Penang, Malaysia, 5King Saud University, Riyadh, Saudi Arabia

PHS104  F9  pgA265  PROTON PUMP INHIBITOR PRESCRIBING TREND IN THE US AMBULATORY SETTING
Rane P1, Aparasu RR2, Guha S2, 1University of Houston, Houston, TX, USA, 2University of Texas Health Science Center, Houston, TX, USA

PHS105  F10  pgA265  IMPORTANCE OF JOINT WORK BETWEEN PHARMACIST AND PHYSICIAN IN THE RATIONAL DRUG USE IN PATIENTS WITH OSTEOPOROSIS,
Strait J1, Galvis MJ2, Caro M3, Segura AM4, 1CES University, Medellin, Colombia, 2Nacional University, Bogota, Colombia, 3Antioquia University, Bogota, Colombia, 4Antioquia University, Medellin, Colombia

PHS107  F12  pgA265  PREVALENCE AND DETERMINANTS OF LOW-COST GENERIC DRUG PROGRAM USE IN THE PRIVATELY-INSURED ADULT POPULATION
Pauly N1, Brown J, University of Kentucky, Lexington, KY, USA

PHS108  F13  pgA266  SOCIOECONOMIC DIFFERENTIAL IN ONE-YEAR SURVIVAL AFTER HOSPITALIZATION FOR ISCHEMIC STROKE: THE EFFECT OF ACUTE AND POST-ACUTE CARE-PATHWAYS IN LAZIO REGION, ITALY
Belludi V1, Sciattella P, Agabiti N, Di Martino M, Di Domenicantonio R, Davoli M, Fusco D, Department of Epidemiology of the Regional Health Service - Lazio, ROME, Italy

PHS109  F14  pgA266  GENDER DISTRIBUTION OF OUTPATIENT CARE PHYSIOTHERAPY SERVICES FOR LOW BACK PAIN IN HUNGARY
Járomi M1, Hanzel A2, Rátgéber L2, Juhász K3, Sebestyén A4, Boncz I5, Csákyári T6, Vajda R1, Molics B1, 1University of Pécs, Pécs, Hungary, 2Ratgeber Academia, Pécs, Hungary, 3National Health Insurance Fund Administration, Pécs, Hungary, 4University of Pécs, Zalaegerszeg, Hungary

PHS110  F15  pgA266  REFERRAL RECOMMENDATIONS MADE BY COMMUNITY HEALTH WORKERS ON THE ‘PATIENTS’ REFERRAL SLIPS. BRIDGING HOUSEHOLDS TO SUSTAINABLE HEALTHCARE; KENYAN EXPERIENCE
Mogere DM1, Loum CS, Kaseje D, Great Lakes University of Kisumu, Nairobi, Kenya

PHS111  F16  pgA266  FREQUENT EMERGENCY DEPARTMENT USE AMONG NON-ELDERLY ADULTS: ANALYSIS OF MULTI-STATE MEDICAID CLAIMS DATA
Agarwal P1, Bias T2, Frisbee S3, Sambamoorthi N4, Bose S5, Madhavan SS6, Sambamoorthi U7, West Virginia University, Morgantown, WV, USA, 2Northwestern University, Chicago, IL, USA

PHS112  G1  pgA266  HUMAN PAPILLOMAVIRUS (HPV) VACCINATION DURING WELL-CHILD VISITS IN PRIVATELY INSURED MALES 9-21 YEARS OF AGE IN THE UNITED STATES IN 2012

Ito C1, Nishikino R1, Onishi Y2, 1JMDC Co., Ltd., Tokyo, Japan, 2Creativ-Celltech K.K., Tokyo, Japan
AGE AND GENDER DISTRIBUTION OF OUTPATIENT CARE PHYSIOTHERAPY SERVICES FOR SHOULDER AND UPPER ARM INJURIES IN HUNGARY

Molics B¹, Boncz I¹, Endreí D¹, Rátgéber L¹, Juhász K¹, Sebestyén A¹, Vajda R¹, Csákárvári T¹, Járomi M¹, University of Pécs, Pécs, Hungary, ²Rátgéber Academia, Pécs, Hungary, ³National Health Insurance Fund Administration, Pécs, Hungary, ⁴University of Pécs, Zalaegerszeg, Hungary

HEALTHCARE COVERAGE, EXPENDITURES AND POPULATION HABITS IN ARGENTINA

Najun Dubos L, Cuberos M, Benitez J, Roche Argentina, Buenos Aires, Argentina

THE IMPACT OF NCMS POLICIES ON INPATIENT HEALTH EXPENDITURE AND ITS EQUALITY IN RURAL CHINA

Guo N¹, Wang J¹, Shi LW¹, Han S¹, Zhu D¹, Guan XD¹, Department of Pharmaceutical Science, Peking University, Beijing, China, ²Shandong University, Jinan, China, ³International Research Center of Medical Administration, Peking University, Beijing, China, ⁴Center for Health Policy and Management, Institute of Medical Information & Library, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

REDUCING MATERNAL AND CHILD MORTALITY IN GHANA: IS NATIONAL HEALTH INSURANCE SCHEME’S FREE MATERNAL CARE PROGRAMME HELPING?

Nsiah-Boateng E, National Health Insurance Authority, Accra, Ghana

DEFINITION OF END-OF-LIFE PERIOD AND QUALITY BENCHMARKS IN TERMINAL CANCER CARE: A LITERATURE REVIEW

Sieluk J¹, Goto D¹, Hanna N¹, Mullins CD¹, University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Maryland Department of Surgery, Division of General and Oncologic Surgery, Baltimore, MD, USA

THE IMPACT OF PATIENT CENTERED MEDICAL HOME IN A MANAGED MEDICAID POPULATION

Chu L, University of Southern California, Los Angeles, CA, USA

PREVENTING CERVIX-UTERUS CANCER IN ARGENTINA. STRUCTURE, ORGANIZATION AND RESULTS

Maceira D, Center for the Study of State and Society (CEDES), Buenos Aires, Argentina

A NOVEL STILLBIRTH AUDIT TOOL IMPLEMENTATION IN GHANA: ASSESSMENT OF DEPLOYMENT IN 2014

Davies-Teye BB¹, Baison HM¹, Oduro-Mensah E², Vanotoo L², Drifney Consult Ltd, Accra, Ghana, ³Greater Accra Regional Health Directorate Ghana Health Services, Accra, Ghana, ⁴Ridge Hospital OPD, Accra, Ghana

DIFFERENCES IN BREAST CANCER SCREENING RATES IN MEDICARE ADVANTAGE NON-DUAL ELIGIBLE MEMBERS, DUAL ELIGIBLES ENROLLED IN SPECIAL NEED PLANS AND OTHER HEALTHCARE PLANS

Pulungan Z, Teigland C, Mehta S, Parente A, Inovalon, Bowie, MD, USA

DIFFERENCES IN CHARACTERISTICS, HEALTH SERVICE UTILIZATION AND COST BETWEEN OLDER HOSPITALIZED LUNG CANCER PATIENTS WITH OR WITHOUT ASTHMA

Roy D¹, Blanchette CM², Zacherle E²,¹University of North Carolina, Charlotte, Charlotte, NC, USA, ²University of North Carolina at Charlotte, Charlotte, NC, USA

POTENTIAL SAVINGS IN HEALTHCARE SPENDING ON “LOW-VALUE” INTERVENTIONS: CASE STUDY OF ARTHROSCOPIC KNEE SURGERY

Rane PB¹, Olchanski N¹, Saret CJ¹, Neumann PJ¹, Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA, ²Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

IS VISUAL IMPAIRMENT ASSOCIATED WITH INCREASED HOSPITALIZATION? A RETROSPECTIVE COHORT STUDY OF COMMUNITY-DWELLING MEDICARE BENEFICIARIES

Tsang Y, Tom S, Onukwugha E, University of Maryland School of Pharmacy, Baltimore, MD, USA

HEALTH SERVICES UTILIZATION AND COSTS AMONG EMPLOYED ADULTS WITH DEPRESSION

Gangan N, Yang Y, University of Mississippi, University, MS, USA

MEDICAL RESOURCE UTILIZATION OF ACUTE MYOCARDIAL INFARCTION PATIENTS WITH READMISSION: A RETROSPECTIVE ANALYSIS OF HOSPITALIZATION DATA FROM BEIJING MEDICAL INSURANCE DATABASE

Wen L¹, Wu J¹, Yang L¹, Peking University, Beijing, China, ²Bayer, Beijing, China

EFFECTS OF OVERWEIGHT AND OBESITY ON HEALTH SERVICE USE AND EXPENDITURES AMONG U.S. ADULTS WITH CHRONIC RENAL DISEASE

Zanwar P¹, Franzini L², University of Houston Clear Lake, Houston, TX, USA, ²University of Maryland School of Public Health, College Park, MD, USA

PREDICTING MEDICAL REIMBURSEMENT AMOUNT - WHAT FACTORS DRIVE THE MEDICAL COST
TREND
Wang QC, Sicker A, Chawla R, Nigam S, Independence Blue Cross, Philadelphia, PA, USA

PHS131 G18 pgA269 OUT-OF-POCKET HEALTHCARE EXPENDITURES AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Kang HA, Barner JC, The University of Texas at Austin, Austin, TX, USA

PHS132 G19 pgA269 COST STUDY ON PROVINCIAL GENERAL HOSPITALS
Gantugs Y1, Otgonbayar D2, Tsolmongerel T3, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia, 1Mongolian Medical Education Association, Ulaanbaatar, Mongolia, 2MOH, Ulaanbaatar, Mongolia

PHS133 G20 pgA270 MEDICAL RESOURCE UTILIZATION OF ISCHEMIC STROKE PATIENTS WITH READMISSION: A RETROSPECTIVE ANALYSIS OF HOSPITALIZATION DATA FROM BEIJING MEDICAL INSURANCE DATABASE
Wen L1, Wu J2, Yang L1, Peking University, Beijing, China, 2Bayer, Beijing, China

PHS134 G21 pgA270 THE MARKET FOR HEPATITIS C SERVICES IN ALBERTA
Thanh NX1, Misurski D2, Waye A3, Jacobs P3, Tyrrell DL3, Institute of Health Economics, Edmonton, AB, Canada, 1Abbvie, Chicago, IL, USA, 2University of Alberta, Edmonton, AB, Canada

PHS135 H1 pgA270 COST OF PRIMARY AND SECONDARY HEALTHCARE UTILIZATION FOR PATIENTS WITH IRRITABLE BOWL SYNDROME CALCULATED USING ROUTINELY COLLECTED ELECTRONIC RECORDS TO ASSESS THE IMPACT OF SECONDARY CARE REFERRAL
Canavan C, Card T, West J, University of Nottingham, Nottingham, UK

PHS136 H2 pgA270 UTILIZATION AND PAYMENT OF ERCP-RELATED OPERATIONS AND MEDICAL SUPPLIES IN CHINA BMI INPATIENTS
Cui B1, Wang L2, Xiong X2, Li J2, Peking University, Beijing, China, 2China Health Insurance Research Association, Beijing, China

PHS138 H3 pgA270 COLORECTAL CANCER (CRC) COSTS IN THE US: FINDINGS FROM THE MEDICAL EXPENDITURE PANEL SURVEY 2008-2012
Haider MR1, Qureshi Z2, Horner R2, Xirasagar S1, Khan MM3, University of South Carolina, Columbia, SC, USA, 1University of South Carolina, COLUMBIA, SC, USA

PHS139 H4 pgA271 PREDICTORS AND TRENDS IN UTILIZATION OF CERVICAL CANCER PREVENTIVE CARE SERVICES IN THE U.S
Gunjal SS1, Wang X2, Mgberie O2, Essien EJ2, 1Precision Health Economics, Austin, TX, USA, 2University of Houston, Houston, TX, USA, 3Houston Department of Health and Human Services, Houston, TX, USA

PHS140 H5 pgA271 PATIENT RACE/ETHNICITY, PERCEIVED QUALITY OF HEALTHCARE AND HOSPITALIZATIONS: AN INVESTIGATION USING THE MEDICAL EXPENDITURE PANEL SURVEY
Ampaabeng SK1, Onukwugha E2, 1IMPAQ International, Columbia, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA

PHS141 H6 pgA271 POINT-OF-CARE, REAL-TIME DECISION SUPPORT TOOLS: A PATHWAY COMPLIANCE SOLUTION BUT ONLY WHEN THEY ARE USED
Feinberg BA1, Lanej J2, English S3, Drenning J4, 1Cardinal Health, Dublin, OH, USA, 2Cardinal Health, Locust Grove, GA, USA, 3Cardinal Health, Conyers, GA, USA, 4Cardinal Health, Dallas, TX, USA

PHS142 H7 pgA271 STATUS OF BIRTHS MADE WITHIN SUS IN BRAZIL
Sansone D, Etto H, Andrade TR, Araujo GT, Fonseca M, AxiaBio, São Paulo, Brazil

PHS143 H8 pgA271 IMPACT OF MEDICATION THERAPY MANAGEMENT (MTM) PILOT PROGRAM ON HEALTHCARE UTILIZATION AND COSTS AMONG TEXAS MEDICAID PATIENTS WITH HYPERTENSION
Makhinova T1, Barner JC1, Lawson KA1, Roberson K2, 1The University of Texas at Austin, Austin, TX, USA, 2Texas Pharmacy Association, Austin, TX, USA

PHS144 H9 pgA271 CHARACTERISTICS OF DRUG THERAPY PROBLEMS AND RESPONSE RATE IN TELEPHONIC COMPREHENSIVE MEDICATION REVIEWS PROVIDED TO 2014 MEDICARE PART D BENEFICIARIES
Wong J, Scott and White Health Plan, Temple, TX, USA

PHS145 H10 pgA272 IDENTIFYING KEY FACTORS FOR TARGETING PATIENTS MOST SUITABLE FOR COMMUNITY HEALTH WORKER PROGRAM
Wang QC, Nandyala P, Chawla R, Nigam S, Independence Blue Cross, Philadelphia, PA, USA

PHS146 H11 pgA272 EVALUATION OF A PRE HOSPITAL CARE PROGRAM FOR PATIENTS WITH TRIAGE III-IV
Romero M1, Torres A2, Barrios E3, Villegas J1, Lee J2, 1Salutia Foundation, Bogota, Colombia, 2Salutia’s Foundation- Research center in economy, management and health technologies, Bogota, Colombia, 3Coomeva Group, Cali, Colombia

PHS147 H12 pgA272 IMPACT OF A COMMUNITY PHARMACY-BASED TRANSITION OF CARE PROGRAM ON HOSPITAL READMISSIONS AT 30 AND 180 DAYS
Ni W1, Colayco D2, McCombs J3, 1University of Southern California, Los Angeles, CA, USA, 2Komoto Healthcare, Bakersfield, CA, USA
**PHS149 H13 pgA272** USE OF PRESCRIPTION MONITORING PROGRAMS BY PRIMARY CARE PHYSICIANS: RESULTS OF A NATIONAL SURVEY  
Hwang CS1, Rutkow L2, Turner L3, Lucas E4, Alexander GC4, Food and Drug Administration, Silver Spring, MD, USA, 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Johns Hopkins School of Public Health, Center for Drug Safety and Effectiveness, Baltimore, MD, USA

**PHS150 H14 pgA272** COMPARISON OF GUIDELINES AND MANAGEMENT FOR GASTRIC CANCER SCREENING BETWEEN KOREA AND JAPAN  
Hamashima C1, Kim Y2, Choi KS2, 1National Cancer Center, Tokyo, Japan, 2National Cancer Control Institute, Gyeonggi-do, South Korea

**PHS151 H15 pgA272** IMPACT OF CASE MANAGEMENT NURSES ON CANCER PATIENTS: A SYSTEMATIC REVIEW  
Bregman C1, Doutriau A2, Cognet M2, Gauthier A2, Pourcel G3, Ferrari C3, Viguier J1, 1Amaris, Paris, France, 2Amaris, London, UK, 3Institut National du Cancer, Boulogne Billancourt, France

**PHS152 H16 pgA273** AN INNOVATIVE CLOUD-BASED PLATFORM FOR IMPLEMENTING PERFORMANCE-BASED RISK-SHARING ARRANGEMENTS (PBRSAS) IN ONCOLOGY SETTINGS  
De Rosa M1, Martini N2, Ortali M1, Esposito I2, Roncadori A1, CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, 1Accademia Nazionale di Medicina, Roma, Italy

**PHS153 H17 pgA273** SOCIOECONOMIC INEQUALITIES IN PRENATAL CARE UTILIZATION IN PAKISTAN  
Jahangeer RA, Pakistan Institute of Development Economics (PIDE), Islamabad, Pakistan

**PHS154 H18 pgA273** ESTIMATING THE HEALTH BENEFITS OF MEETING THE HEALTHY PEOPLE 2020 OBJECTIVES FOR REDUCING INVASIVE COLORECTAL CANCER INCIDENCE IN THE UNITED STATES  
Hung M1, Ekwueme DD, Wang J3, Division of Cancer Prevention and Control, US Centers for Disease Control and Prevention, Chambless, GA, USA, 2Centers for Disease Control and Prevention, Chambless, GA, USA, 3Department of Public Health, National Cheng Kung University College of Medicine, Tainan, Taiwan

**PHS155 H19 pgA273** MORAL HAZARD AND HEALTH INSURANCE: EXAMINING THE ROLE OF PRIVATE VS. PUBLIC INSURANCE IN PROSTATE CANCER SCREENING, PROSTATE CANCER DIAGNOSIS AND PATIENT SATISFACTION WITH PROSTATE CANCER CARE  
Zanwar P, University of Houston Clear Lake, Houston, TX, USA

**PHS156 H20 pgA273** HEALTHCARE BURDEN OF CERVICAL CANCER IN A NATIONAL MEDICAID MANAGED CARE POPULATION  
Joshi N, Khanna R, Pace P, Banahan III B, University of Mississippi, University, MS, USA

**PHS157 H21 pgA274** NONCOMMUNICABLE DISEASE PREVENTION AND CONTROL IN MONGOLIA: A POLICY ANALYSIS  
Chimeddamba O1, Peeters A2, Walls H3, Joyce C1, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia, 2Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia, 3London School of Hygiene and Tropical Medicine, London, UK

**PHS158 I1 pgA274** FACTORS PREDICTING RECEIPT OF PROSTATE SPECIFIC ANTIGEN (PSA) TESTING: EVIDENCE FROM THE NATIONAL AMBULATORY MEDICAL CARE SURVEY (NAMCS) DATA  
Haider MR1, Qureshi Z1, Horner R1, Bennett C1, University of South Carolina, Columbia, SC, USA, 2University of South Carolina College of Pharmacy, Columbia, SC, USA

**PHS159 I2 pgA274** THE BURDEN OF GOUT IN A CANADIAN PRIMARY CARE POPULATION  
Williams DM1, Cowan C1, Gendron A1, Goodfield J2, Oraichi D2, Fischer A2, Borrelli R2, Liu N2, Dziarmaga A1, AstraZeneca Canada Inc., Mississauga, ON, Canada, 2IMS Brogan, Mississauga, ON, Canada

**PHS160 I3 pgA274** EVALUATING THE PREVALENCE OF MENINGITIS IN HAZARA DIVISION, KPK PAKISTAN  
Azhari SA, Khan GN, Wazir FW, Izhar IH, COMSATS Institute of Information Technology, Abbottabad, Pakistan

**PHS161 I4 pgA274** RECENT TRENDS IN BACTERIAL INFECTION-RELATED HOSPITALIZATIONS IN THE US  
Kurosky SK, Reese ES, Candrillii S, RTI Health Solutions, Research Triangle Park, NC, USA

**PHS162 I5 pgA274** PREVALENCE OF MENTAL HEALTH DISORDERS AND ACCESS TO CARE AMONG CHILDREN ENROLLED IN THE MISSISSIPPI MEDICAID  
Nunna S1, Shah R1, Banahan III B1, Hardwick SP1, Clark JP1, University of Mississippi, University, MS, USA, 2Mississippi Division of Medicaid, Jackson, MS, USA

**PHS163 I6 pgA275** IS THE UPTAKE OF VOLUNTARY MEDICAL MALE CIRCUMCISION INFLUENCED BY LEVEL OF EDUCATION, MARITAL STATUS AND MAIN SOURCE OF INCOME? CASE STUDY OF WESTERN KENYA  
Mogere DM, Great Lakes University of Kismu, Nairobi, Kenya

**PHS165 I7 pgA275** IMPACT OF COMMUNITY BASED THERAPY ON CHILDREN WITH MENTAL HEALTH DISORDERS: A HEALTH TECHNOLOGY ASSESSMENT  
Chahar A1, Gulati R1, Sharma J1, Likhar N2, Dang A2, National Health Systems Resource Centre, Division of Healthcare Technology, New Delhi, India, 1MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

**PHS166 I8 pgA275** INCREASING HOUSEHOLDS’ ACCESS TO HEALTHCARE; LINKING CLINICIANS TO COMMUNITY HEALTH WORKERS THROUGH COUNTER REFERRAL COMMENTS
**DISEASE: SPECIFIC STUDIES**

**NEUROLOGICAL DISORDERS - Clinical Outcomes Studies**

**PND1 J7 pgA277 EFFECTIVENESS OF PHARMACOTHERAPY IN CHILDREN WITH SYMPTOMATIC EPILEPSY**
- Bhardwaj A 1, Bansal D 1, Azad C 1, National Institute of Pharmaceutical Education and Research, Mohali, India
  2, Government Medical College and Hospital, Chandigarh, India

**PND2 J8 pgA277 COMPARATIVE STUDY OF THE INFLUENCE OF BIAPENEM AND MEROPENEM ON VALPROIC ACID BLOOD CONCENTRATION**
- Tang L 1, Suzhou Municipal Hospital, Suzhou, China

**PND3 J9 pgA278 SYSTEMATIC LITERATURE REVIEW OF TREATMENTS OF CHRONIC CLUSTER HEADACHE**
- Medic G 1, Thayaneswar S 1, Papadimitropoulou K 2, Staubel F 2, Karabis A 3, MAP Group, Houten, The Netherlands
  4, Medtronic International, Tolenchenaz, Switzerland

**PND4 J10 pgA278 RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH NECESSARY INTERVENTIONS FOR PARKINSON DISEASE**
- Crispo J 1, Willis AW 1, Fortin Y 1, Emons MF 2, Bjerre LM 3, Kohen DE 3, Perez Llioret S 3, Mattison DR 3, Krewski D 3, University of Ottawa, Ottawa, ON, Canada
  4, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
  5, Cerner Corporation, Culver City, CA, USA
  6, Catholic University, Buenos Aires, Argentina
  7, Risk Sciences International, Ottawa, ON, Canada

**PND5 J11 pgA278 SPECIFICITY AND SENSITIVITY OF AQUAPORIN 4 ANTIBODY DETECTION TESTS IN PATIENTS WITH**
NEUROLOGY - Cost Studies

PND17 K8 pgA280 ALEMTUZUMAB BUDGET IMPACT ANALYSIS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE US
Celestin C1, Wandstrat T1, Coleman C1, Genzyme, a Sanofi company, Cambridge, MA, USA, 2University of Connecticut/Hartford Hospital Evidence-Based Practice Center, Hartford, CT, USA

PND18 K9 pgA280 BUDGET IMPACT OF ADDING PEGINTERFERON BETA-1A TO THE FORMULARY FOR THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS
Mauskopf JA1, Graham J1, Fay-Azhar M1, Kinter E1, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3RTI-Health Solutions, Research Triangle Park, NC, USA, 4Biogen Idec, Weston, MA, USA
HOSPITAL BUDGET IMPACT OF SUGAMMADEX (BRIDION®) FOR REVERSAL OF NEUROMUSCULAR BLOCKADE
Insinga R, Maiiese EM, Devine S, Merck & Co., Inc., Kenilworth, NJ, USA

BUDGET IMPACT OF CHOOSING REBIF® AS THE INTERFERON OF CHOICE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM
Fujii RK1, Wong S2, Junqueira M1, Merck Serono, São Paulo, Brazil, 1EMD Serono, Inc., Billerica, MA, USA

CALculating the costs of adverse drug reactions from post-marketing data: Implications for outcomes research
Hoffman KB, Dimbil M, AdverseEvents, Inc., Santa Rosa, CA, USA

AN ASSESSMENT OF FACTORS ASSOCIATED WITH HIGH COSTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS (MS) RECEIVING DISEASE-MODIFYING DRUG (DMD) THERAPY
Locklear JC1, Frean M1, Phillips AL1, Menzin J2, EMD Serono, Inc., Rockland, MA, USA, 1Boston Health Economics, Inc., Waltham, MA, USA

A COMPARISON OF HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS IN ADULTS WITH GENERALIZED CONVULSIVE SEIZURES (GCS)
Li X1, Barghout V2, Wang Z1, Eisai, Inc., Woodcliff Lake, NJ, USA, 1VEB Healthcare LLC., Morristown, NJ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA

PRICE ANALYSIS OF MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES MARKETED IN THE US
Bin Sawad A1, Seoane-Vazquez E1, Rodriguez-Monguio R1, MCPHS University, Boston, MA, USA, 1School of Public Health and Health Sciences, UMASS, Amherst, MA, USA

THE ECONOMIC BURDEN OF SPINAL MUSCULAR ATROPHY
Armstrong EP1, Malone DC2, Yeh W3, Dahl GJ4, Lee R5, Siciignano N6, 1Strategic Therapeutics, LLC, Oro Valley, AZ, USA, 2University of Arizona, Tucson, AZ, USA, 3Biogen Idec, Cambridge, MA, USA, 4Naval Medical Center Portsmouth, Portsmouth, VA, USA, 5Naval Medical Research Unit Dayton, Dayton, OH, USA, 6Health ResearchTx, Trevose, PA, USA

OUT OF POCKET COST FOR PEDIATRIC EPILEPSY MANAGEMENT: RESULTS FROM MALAYSIAN POPULATION
Kashyap M, Bahari B, AIMST University, Semeling, Malaysia

ANALYSIS OF MEDICAL COSTS OF RRMS RELAPSES
Nakamura Y, Milliman, Tokyo, Japan

A RETROSPECTIVE ANALYSIS OF THE ECONOMIC BURDEN AMONG PATIENTS DIAGNOSED WITH CHRONIC MIGRAINE USING THE VETERANS HEALTH ADMINISTRATION MEDICAL DATA
Mao X1, Shrestha S1, Baser O1, Wang L2, 1University of Texas at Dallas and STATinMED Research, Plano, TX, USA, 2STATinMED Research, Plano, TX, USA, 3STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA

HEALTH CARE RESOURCE UTILIZATIONS AND COSTS AMONG MIGRAINE PATIENTS IN THE U.S. MEDICAID POPULATION
Huang A1, Shrestha S1, Baser O2, Yuce H3, Wang L11, 1STATinMED Research, Plano, TX, USA, 2STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, 3City University of New York & STATinMED Research, New York, NY, USA

COST-EFFECTIVENESS ANALYSIS OF IPX066 IN ADVANCED PARKINSON'S DISEASE
Arnold RJ1, Frasco MA1, Layton A1, Rustay NR2, Chen S1, Quorum Consulting, San Francisco, CA, USA, 1Impax Laboratories, Inc., Hayward, CA, USA

COST EFFECTIVENESS OF LEVODOPA/Carbidopa intestinal gel in ireland
Bai R, Egan KM, McCarthy J, AbbVie Ltd., Dublin, Ireland

THE COST-EFFECTIVENESS OF DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
Bozkaya D1, Livingston TP1, Migliaccio-Walle K1, Mehta S2, Odom T1, Xcenda, Palm Harbor, FL, USA, 1Biogen Idec, Weston, MA, USA

“COST EFFECTIVENESS ANALYSIS OF MOST COMMONLY PRESCRIBED DRUGS IN MIGRAINE”
Upreti AR, Kathmandu University, kathmandu, Nepal

COST EFFECTIVENESS OF EARLY TREATMENT OF PARKINSON’S DISEASE IN MEXICO
Marquez M1, Diaz JP2, Pizarro M3, Ibarra A, Cervantes A4, Rodriguez M5, Soto H1, 1Universidad Autonoma Metropolitana, Mexico D.F., Mexico, 2Universidad Nacional Autonoma de Mexico, Mexico D.F., Mexico, 3Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, 1Institute Nacional de Neurologia y Neurocirugia, Mexico D.F., Mexico

THE COST-EFFECTIVENESS OF Lisdexamfetamine Dimesylate for the treatment of binge eating disorder
Ágh T1, Pawaskar M2, Voko Z1, Nagy B1, Lachaine J1, Syreon Research Institute, Budapest, Hungary, 1Shire
THE IMPACT OF NEUTRALIZING ANTIBODY TESTING ON THE COST-EFFECTIVENESS OF INJECTABLE DISEASE MODIFYING TREATMENTS FOR RELAPSING REMITTING MULTIPLE SCLEROSIS
Andreykiv M¹, Plich A¹, Prüfert A², Heemstra L², Van Engen A²,¹Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands, ²Quintiles Consulting, Hoofddorp, The Netherlands

TRACKING HEALTHCARE UTILIZATION (COST) IN PSEUDOBULBAR AFFECT PATIENTS TREATED WITH NUDEXTA
Palmgren M¹, Cyhniuk A², Yonan C³, Potente E³,¹IntOvation, Marietta, GA, USA, ²AC Analytical Solutions, Barrington, IL, USA, ³Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA

HEALTH CARE RESOURCE UTILIZATION BEFORE AND AFTER NATALIZUMAB INITIATION AMONG MULTIPLE SCLEROSIS PATIENTS IN GERMANY
Watson C¹, Prosser C², Braun S², Landsman-Blumberg P³, Naoshy S¹, Biogen Idec, Cambridge, MA, USA, ¹Xcenda GmbH, Hannover, Germany, ²Xcenda LLC, Palm Harbor, FL, USA

SKELETAL MUSCLE ACTIVITY AND RESOURCE TOOL FOR SPORADIC INCLUSION BODY MYOSITIS (SMART-SIBM): CHARACTERIZATION OF RESOURCE UTILIZATION AND FINANCIAL BURDEN EXPERIENCED BY SIBM PATIENTS
Barghout V¹, DeMuro C², Price M², Lewis S², Tseng B³,¹VEB Healthcare LLC., Morristown, NJ, USA, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³Novartis Pharmaceuticals, Cambridge, MA, USA

NEUROLOGICAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

DESCRIPTION OF PROPHYLACTIC DRUG UTILIZATION PATTERNS IN MIGRAINE PATIENTS
Shei A¹, Woolley JM², Desai PR², Enloe CJ¹, Kirson NY¹, Birnbaum HG¹, Corey-Lisle PK², Sapsa S²,¹Analysis Group, Inc., Boston, MA, USA, ²Amgen Inc., Thousand Oaks, CA, USA, ³EMD Serono, Inc., Rockland, MA, USA

A REVIEW OF METHODOLOGIES USED TO ASSESS ADHERENCE TO DISEASE MODIFYING THERAPIES AMONG PATIENTS WITH MULTIPLE SCLEROSIS
Thach A, Chimah C, Makhinova T, Brown C, The University of Texas at Austin, Austin, TX, USA

ADHERENCE AND PERSISTENCE TO ANTI-EPILEPTIC DRUGS AMONG U.S. VETERANS DIAGNOSED WITH EPILEPSY
Velez FF¹, Baser O², Xie L³, Sunovion Pharmaceuticals Inc, Marlborough, MA, USA, ²STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, ³STATinMED Research, Ann Arbor, MI, USA

MEASURING ADHERENCE AND OUTCOME IN TREATMENT OF MULTIPLE SCLEROSIS IN THE GEISINGER CLINIC
Graham JH¹, Hao J², Pitcavage JM¹, Hoegerl CR¹, Jones J², Taylor SR¹, Ryman AM¹, Geisinger Health System, Danville, PA, USA, ²Liberty University, Lynchburg, VA, USA, ³Sutter Health, Research, Development & Dissemination, Walnut Creek, CA, USA, ⁴University of Pittsburgh, Pittsburgh, PA, USA

WHAT ARE PEOPLE WILLING TO PAY FOR WHOLE GENOME SEQUENCING INFORMATION?
Marshall DA¹, Gonzalez JM², Johnson FR³, Pugh A¹, MacDonald KV¹, Douglas MP¹, Phillips KA¹,³Alberta Bone and Joint Health Institute, Calgary, AB, Canada, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³Duke University, Durham, NC, USA, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of California – San Francisco, San Francisco, CA, USA

ESTIMATING THE VALUE OF WHOLE EXOME SEQUENCING FOR PARENTS OF CHILDREN WITH RARE GENETIC DISEASES
Marshall DA¹, MacDonald KV¹, Lopatina E², MacKenzie A³, Hartley T², Boycott K²,¹Alberta Bone and Joint Health Institute, Calgary, AB, Canada, ²University of Calgary, Calgary, AB, Canada, ³Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada

PATIENT-REPORTED OUTCOME MEASURES FOR MULTIPLE SCLEROSIS PHASE IV CLINICAL TRIALS: A SYSTEMATIC REVIEW
Ting J¹, Zhong L¹, Petrillo J¹, Niu C¹, Lee A², Sarda S¹, University of California, San Francisco, San Francisco, CA, USA, ²Biogen Idec, Cambridge, MA, USA, ³University of Southern California, Los Angeles, CA, USA

A NOVEL MEASURE TO ASSESS SELF-REPORTED PHYSICAL FUNCTIONING IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS (SIBM)
DeMuro C¹, Lewis S¹, Pax Lowes L², Alfano L², Tseng B³, Gnanasakthy A¹,³RTI Health Solutions, Research Triangle Park, NC, USA, ²Nationwide Children’s Hospital, Columbus, OH, USA, ³Novartis Pharmaceuticals, Cambridge, MA, USA

UNDERSTANDING THE SUITABILITY OF CYSTIC FIBROSIS-SPECIFIC CLINICAL OUTCOME ASSESSMENTS FOR CLINICAL TRIALS AND TO SUPPORT MEDICAL PRODUCT LABELING
Willgoess TG¹, Trigg A¹, Meysner S¹, Kitchen H¹, Humphrey L¹, Blankenburg M¹, Abacus International, Manchester, UK, ²Bayer HealthCare Pharmaceuticals, Berlin, Germany

THE PARKINSON’S DISEASE QUESTIONNAIRE (PDQ-39) - EVALUATING THE PSYCHOMETRIC PROPERTIES OF AN ELECTRONIC VERSION
Morley D¹, Jenkinson C¹, Dummett S¹, Kelly L¹, Churchman DR², Dawson J¹,³University of Oxford, Oxford,
SEX DIFFERENCES IN OVER-THE-COUNTER SLEEP AID USE IN OLDER ADULTS  
Gross HJ, O’Neil G, Toscani M, Chapnick J, Kantar Health, Princeton, NJ, USA, 2Gerontological Society of America, Washington, DC, USA, 3Ernest Mario School of Pharmacy, Piscataway, NJ, USA, 4Kantar Health, Horsham, PA, USA

BURDEN OF ILLNESS FOR PATIENTS WITH FAMILIAL AMYLOIDOTIC POLYNEUROPATHY (FAP) BEGINS EARLY AND INCREASES WITH DISEASE PROGRESSION  

A NOVEL CONCEPTUAL MODEL OF CYSTIC FIBROSIS BASED ON QUALITATIVE PATIENT RESEARCH  

AWARENESS AND KNOWLEDGE OF FOLIC ACID INTAKE FOR THE PREVENTION OF NEURAL TUBE DEFECTS AMONG WOMEN OF CHILDBEARING AGE  
Alwhaibi M, Dwibedi N, Garg R, West Virginia University, Morgantown, WV, USA

QUALITY-OF-LIFE PREDICTORS OF TREATMENT CONTINUATION ON ESPLICARBEPINE ACETATE MONOTHERAPY AMONG SUBJECTS WITH REFRACTORY PARTIAL-ONSET SEIZURES  
Bond TC, Velez FF, Cramer JA, Anastassopoulos KP, Wang X, Sousa R, Rocha F, Blum D, Covance Market Access, Gaithersburg, MD, USA, 2Sunovion Pharmaceuticals Inc., Marlborough, MA, USA, 3Yale University, Houston, TX, USA, 4BIAL, S. Mamede do Coronado, Portugal

TREATMENT SATISFACTION AMONG PATIENTS TREATED WITH MONOTHERAPY AND ADJUNCTIVE ANTIEPILEPTIC DRUG THERAPIES  
Lee LJ, Velez FF, Pomerantz D, DiBonaventura MD, Kantar Health, Foster City, CA, USA, 2Sunovion Pharmaceuticals Inc, Marlborough, MA, USA, 3Kantar Health, Horsham, PA, USA, 4Kantar Health, New York, NY, USA

QUALITY OF LIFE IN NEUROMYELITIS OPTICA: A SYSTEMATIC REVIEW  
Likhar N, Dang A, MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

QUALITY OF LIFE OF PATIENTS WITH PARKINSON’S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS  
Chekani F, Bali V, Aparasu RR, University of Houston, Houston, TX, USA

IMPACT OF YOUNG-ONSET PARKINSON’S DISEASE ON QUALITY OF LIFE – A LITERATURE REVIEW  
Sosnowski L, Kamal KM, Pawar G, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, USA, 2West Virginia University School of Medicine, Morgantown, WV, USA

QUALITY OF LIFE IN ADULT PATIENTS WITH CYSTIC FIBROSIS – A SYSTEMATIC REVIEW  
Parlok MH, Ipatova A, Dashputre AA, Kamal KM, Mylan School of Pharmacy Duquesne University, Pittsburgh, PA, USA, 2Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, USA

DOES HEALTH-RELATED QUALITY OF LIFE EVALUATION IN MULTIPLE SCLEROSIS (MS) MATTER? A REVIEW OF LABELS OF MS PRODUCTS APPROVED BY THE FDA AND EMA  
Acquadro C, Perret C, Arnould B, Mapi Research Trust, Lyon, France, 2Mapi, Lyon, France

WILLINGNESS-TO-PAY FOR NEWBORN GENETIC TESTING FOR SPINAL MUSCULAR ATROPHY  
Lin P, Shi J, Yeh W, Neumann PJ, Tufts Medical Center, Boston, MA, USA, 2Biogen Idec, Cambridge, MA, USA, 3Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

THE EVALUATION OF WORK PRODUCTIVITY IN RELAPSING-REMITTING (RRMS) AND SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) PATIENTS IN EUROPE  
Pike J, Naoshy S, Watson C, Jones E, Adelphi Real World, Manchester, UK, 2Biogen Idec, Cambridge, MA, USA

SURVEY OF PHYSICIANS REGARDING APPLICATION AND UTILITY OF PHARMACOGENOMICS RESULTS IN THE MANAGEMENT OF CHRONIC MEDICAL CONDITIONS  
Delgado A, Villarreal SM, Gurnani P, Rosenblatt K, Koeller JM, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, 2CompanionDx, Houston, TX, USA

TWENTY YEARS OF TRIPTANS IN THE UNITED STATES MEDICAID PROGRAMS: UTILIZATION AND REIMBURSEMENT TRENDS FROM 1993-2013  
Xia Y, Kelton CM, Wige PR, Guo JJ, University of Cincinnati, Cincinnati, OH, USA

SPECIALTY TIER COST SHARING AND USE OF DISEASE MODIFYING THERAPIES AMONG MEDICARE
PSY68 N3 pgA289 TRENDS ASSOCIATED WITH IMPLEMENTING AND LIFTING A STEP THERAPY POLICY FOR PREGABALIN IN THE HUMANA MEDICARE POPULATION: AN INTERRUPTED TIME SERIES ANALYSIS
Null KD1, Moll K1, Cappelleri JC1, Sadovsky A1, Parsons B2, Pasquali MK1, Comprehensive Health Insights, Louisville, KY, USA, 2Pfizer Inc, Groton, CT, USA, 3Pfizer Inc, New York, NY, USA

PSY69 N4 pgA289 HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH RESCUE MEDICATION USE IN ADULT PATIENTS WITH SEIZURE CLUSTERS: A RETROSPECTIVE CHART REVIEW
Vazquez B1, Sidovar M1, Squillace D2, Wu E3, Macaulay D3, Sorg R3, Guo A4, Comprehensive Epilepsy Center, New York, NY, USA, 2Acorda Therapeutics, Inc., Ardsley, NY, USA, 3Analysis Group, Inc., New York, NY, USA

PSY70 N5 pgA290 IMPACT OF WALKING IMPAIRMENT ON HEALTHCARE RESOURCE UTILISATION IN MULTIPLE SCLEROSIS PATIENTS
Liu Y1, Pike J2, Lee A1, Hibbert C3, Hoskin B4, Biogen Idec, Cambridge, MA, USA, 2Adelphi Real World, Manchester, UK, 3Biogen Idec International, Zug, Switzerland, 4Adelphi Real World, Macclesfield, MA, USA

PSY71 N6 pgA290 HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH DALFAMPRIDINE EXTENDED RELEASE IN MULTIPLE SCLEROSIS: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS
Krieger S1, Palli SR2, Grabner M2, Elder J1, Aupperle P1, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 2CTI Clinical Trial & Consulting, Cincinnati, OH, USA, 3HealthCore Inc., Wilmington, DE, USA, 4Acorda Therapeutics, Inc., Ardsley, NY, USA

PSY72 N7 pgA290 PARKINSON'S DISEASE AND CAREGIVER BURDEN: RESULTS FROM THE NATIONAL ALLIANCE OF CAREGIVING SURVEY
Bhattacharjee S1, Metzger A2, Tworek C2, Wei W2, Pan X2, Sambamoorthi U3, The University of Arizona, Tucson, AZ, USA, 2West Virginia University, Morgantown, WV, USA, 3Sanofi US LLC, Bridgewater, NJ, USA, 4Evidera LLC, Lexington, MA, USA

PSY73 N8 pgA290 METHODOLOGICAL ISSUES IN CLASSIFYING ADJUNCT ANTI EPILEPTIC DRUG (AED) TREATMENT IN CLAIMS DATA: ANALYSIS OF THE EFFECT OF THE MINIMUM AED CO-ADMINISTRATION PERIOD
Brook RA1, Smeeding JE1, Young JW1, Velez FF1, The JeSTARx Group, Newfoundland, NJ, USA, 2The JeSTARx Group, Dallas, TX, USA, 3HCMS Group, Cheyenne, WY, USA, 4Sunovion Pharmaceuticals Inc, Marlborough, MA, USA

PSY74 N9 pgA290 ORAL DISEASE MODIFYING THERAPY FOR MULTIPLE SCLEROSIS: IS THIS THE NEW NORMAL?
Johnson BH, Truven Health Analytics, Cambridge, MA, USA

PSY75 N10 pgA291 SLEEP MEDICATION USERS AND THEIR CHARACTERISTICS
Anupindi VR1, Shah D1, Vaidya V1, University of Toledo, Toledo, OH, USA

PSY76 N11 pgA291 A DESCRIPTIVE ANALYSIS OF TIME TO FIRST TREATMENT WITH DISEASE-MODIFYING DRUGS (DMDS) IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE SCLEROSIS (MS)
Phillips AL1, Edwards NC2, Sutherland S2, EMD Serono, Inc., Rockland, MA, USA, 2Health Services Consulting Corporation, Boxborough, MA, USA, 3Boston Health Economics, Inc., Waltham, MA, USA

PSY77 N12 pgA291 TREATMENT PATTERNS OF MONOTHERAPY VERSUS COMBINATION ANTI EPILEPTIC DRUG THERAPY IN PATIENTS WITH EPILEPSY
Gupte KP1, Rascati KL1, Wilson JP1, The University of Texas at Austin, College of Pharmacy, Austin, TX, USA

SYSTEMIC DISORDERS/CONDITIONS - Clinical Outcomes Studies

PSY1 N13 pgA291 RISK OF GLUCOCORTICOID-RELATED ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: FINDINGS FROM A 12-YEAR LONGITUDINAL FOLLOW-UP STUDY IN TAIWAN
Chen H1, Shen L1, Hsu P1, Shen C1, Hall SA2, Hsiao F1, National Taiwan University, Taipei, Taiwan, 2Biogen Idec, Cambridge, MA, USA

PSY2 N14 pgA291 A REVIEW OF INTRAOPERATIVE INTERVENTIONS TO PREVENT STAPLE LINE LEAKS AND BLEEDS DURING BARIATRIC SURGICAL PROCEDURES
Ghosh SK1, Roy S2, Chekan E3, Fegelman E1, Johnson & Johnson (Ethicon), Cincinnati, OH, USA, 2Johnson & Johnson (Ethicon), Somerville, NJ, USA, 3Johnson & Johnson (Ethicon), Cincinnati, OH, USA

PSY3 N15 pgA292 RISK OF CARDIOVASCULAR, GASTROINTESTINAL, AND RENAL ADVERSE EVENTS ASSOCIATED WITH DICLOFENAC IMMEDIATE AND EXTENDED RELEASE DRUG PRODUCTS: AN OBSERVATIONAL STUDY USING US CLAIMS DATA
Mladsi DM1, Goyal RK1, Cryer B2, Hopkins WE3, Brater CD4, Korsnes JS5, Candrilli S6, Castellsague J7, Varas-Lorenzo C8, RTI Health Solutions, Research Triangle Park, NC, USA, 2University of Texas Southwestern and VA North Texas Health Care System, Dallas, TX, USA, 3University of Vermont College of Medicine, South Burlington, VT, USA, 4Waltham Health Economics, Inc., Waltham, MA, USA

PSY4 N16 pgA292 LESSONS LEARNED FROM THE PILOT INTRODUCTION OF PEGINESATIDE, A THIRD GENERATION ERYTHROPOIESIS STIMULATING AGENT

PSY5 N17 pgA292 THE VALIDITY OF ALGORITHMS FOR IDENTIFYING SUSPECTED AND CONFIRMED HEPARIN-INDUCED THROMBOCYTOPENIA
Patel VA, Walton SM, Galanter WL, Lee TA, Schumock G, Nutescu EA, University of Illinois at Chicago, Chicago, IL, USA

PSY6 N18 pgA292 MAJOR EARLY COMPLICATIONS FOLLOWING BARIATRIC SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Freeman NL1, Stoll CR1, Carlsson NP1, Calhoun AJ2, Eagon JC2, Colditz GA1, Chang S1, 1Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, St. Louis, MO, USA, 2Division of General Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, St. Louis, MO, USA

PSY7 O1 pgA292 ESTIMATING QUALITY OF LIFE OF PATIENTS WITH LIPODYSTROPHY
Dhanekar P1, Isupov T1, Araujo-Vilar D2, Brown R1, Garg A2, Jae DH2, Rangel Miller V3, Oral E1, Stratton A1, AstraZeneca, Fort Washington, PA, USA, 2University of Santiago de Compostela, Santiago de Compostela, Spain, 3National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA, 4University of Texas Westernmost Medical Center, Dallas, TX, USA, 5Patient Crossroads, La Jolla, CA, USA, 6University of Michigan, Ann Arbor, MI, USA, 7Lipodystrophy United, Los Lunas, NM, USA

PSY8 O2 pgA292 COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH ANKYLOSING SPONDYLITIS (AS) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN THE UNITED STATES (US)
Narayanan S1, Lu Y1, Hutchings R2, Graham CM3, Baynton E4, Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK, 3Ipsos Healthcare, Boston, MA, USA

PSY9 O3 pgA293 APROTININ FREE HEMOSTATIC SEALANT TO REDUCE BLOOD LOSS IN SURGICAL PATIENTS: A SYSTEMATIC REVIEW
Luque A1, Junqueira Junior SM2, Cabra HA3, Andrade PC4, Oliveira FM5, Johnson & Johnson Medical Brazil, Sao Paulo, Brazil, 2Johnson & Johnson Medical Brazil, Sao Paulo, Brazil, 3Johnson & Johnson Medical, Mexico, D.F., 4Mexico

PSY10 O4 pgA293 COMPARATIVE EFFECTIVENESS AND SAFETY OF ARAGTROBAN AND BIVALIRUDIN IN PATIENTS WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA
Patel VA1, Galanter WL1, Lee TA1, Schumock G1, Nutescu EA2, Hohmann SF3, Walton SM3, 1University of Illinois at Chicago, Chicago, IL, USA, 2University HealthSystem Consortium, Chicago, IL, USA

PSY11 O5 pgA293 THE ACTUAL CLINICAL USE OF ANTIFUNGAL DRUGS IN PATIENTS WHO RECEIVED HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPAN: A RETROSPECTIVE DATABASE STUDY
Kawabata I1, li Y1, Yamamoto Y2, Yamazaki T2, Fujimoto Y1, Pfizer Japan Inc, Tokyo, Japan, 2MinaCare co.ltd, Tokyo, Japan

PSY12 O6 pgA293 ROLE OF BEHAVIORAL CONFOUNGING IN THE ASSOCIATION BETWEEN MARIJUANA USE AND BMI IN US ADULTS
Thompson C1, Hay JW2, 1University of Southern California, Santa Monica, CA, USA, 2University of Southern California, Los Angeles, CA, USA

PSY13 O7 pgA293 SECOND PROSPECTIVE, PHARMACOEPIDEMIOLOGIC DATABASE ANALYSIS OF PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE USAGE FROM A REPRESENTATIVE US SAMPLE OF OLDER PATIENTS
Peterson CA1, Steelman X1, Varghese ST1, VIVUS, Inc, Mountain View, CA, USA

PSY14 O8 pgA294 EVALUATING TRENDS IN CHRONIC PAIN PREVALENCE IN THE UNITED STATES VETERANS HEALTH ADMINISTRATION POPULATION
Li L1, Shrestha S1, Baser O2, Wang L1, 1STATinMED Research, Plano, TX, USA, 2STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA

PSY15 O9 pgA294 USE OF HYDROCODONE/ACETAMINOPHEN: PREVALENCE AND ESTIMATING EMERGENCY DEPARTMENT VISITS
Hatfield MD1, Fleming ML, University of Houston, Houston, TX, USA

PSY16 P1 pgA294 MORTALITY RISK IN PATIENTS WITH PSORIASIS
Feldman SR1, Princic N2, Zhao Y3, Barghout V4, Willson T5, Song X2, Guana A6, Herrera V6, 1Wake Forest University School of Medicine, Winston-Salem, NC, USA, 2Truven Health Analytics, Cambridge, MA, USA, 3Novartis Pharmaceuticals, East Hanover, NJ, USA, 4VEB Healthcare LLC., Morristown, NJ, USA, 5Truven Health Analytics, Salt Lake City, UT, USA, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

SYSTEMIC DISORDERS/CONDITIONS - Cost Studies
PSY17 P2 pgA294 BUDGET IMPACT ANALYSIS OF FACTOR REPLACEMENT THERAPY WITH TUROCTOCOG ALFA IN THE TREATMENT OF HEMOPHILIA A
McQuilling CA1, Wang Y1, Wisniewski T2, Cooper D2, lyer NN2, 1Health Economic Consultant, New York, NY, USA, 2Novo Nordisk Inc., Plainsboro, NJ, USA

PSY18 P3 pgA294 MANAGED CARE ORGANIZATION BUDGET IMPACT OF ADDING RECOMBINANT FACTOR VIII FC FUSION
PROTEIN (RFVIIIFC) TO THE FORMULARY FOR THE TREATMENT OF HEMOPHILIA A
Buckley BC1, Livingston TP1, Eldar-Lissai A2, Hall EC3, Biogen Idec, Weston, MA, USA, Biogen Idec, Cambridge, MA, USA

PSY19 P4 pgA294 ECONOMIC IMPLICATIONS OF INCREASING USAGE OF CALCIUM-FREE BALANCED CRYSTALLOID SOLUTIONS (BAL) VERSUS 0.9% SALINE FOR INTRAVENOUS (IV) FLUID THERAPY IN PATIENTS WITH SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) IN US HOSPITALS
Makhibia D1, Munson S2, Khangulov VS2, Peyerl FW2, Paluszkiwicz SM2, Laplante S1, Liu FX1, Baxter Healthcare Corporation, Deerfield, IL, USA, Boston Strategic Partners, Inc., Boston, MA, USA

PSY20 P5 pgA295 THE BUDGET IMPACT OF TREATING PATIENTS WITH NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN (PNP) WITH CAPSAICIN 8% PATCH FOR EITHER PREGABALIN-NAIVE OR PREGABALIN-TREATED PATIENTS IN SCOTLAND
Patel S1, Chambers C2, Garnham A3, Astellas UK, Chertsey, UK, Astellas Pharma EMEA, Chertsey, UK

PSY21 P6 pgA295 COST IMPLICATION OF USING LORCASERIN IN WEIGHT MANAGEMENT PRIOR TO BARIATRIC SURGERY
Wang Z1, Li X2, Knoth R2, Fujioka K3, Eisai Inc., Woodcliff Lake, NJ, USA, Eisai Inc., Woodcliff Lake, NJ, USA, Scripps Health, San Diego, CA, USA

PSY22 P7 pgA295 COST ANALYSIS OF VORICONAZOLE VERSUS CASPOFUNGIN FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS AMONG HIGH-RISK HEMATOLOGIC CANCER PATIENTS IN CHINA
Gao X1, Xue M1, Stephens J1, Chen Y1, Haider S1, Charbonneau C1, Pfizer International, Bethesda, MD, USA, Pfizer Investment Co. Ltd., Beijing, China, Pfizer Inc, Groton, CT, USA, Pfizer Inc, Paris, France

PSY23 P8 pgA295 AN ECONOMIC ANALYSIS OF POSTOPERATIVE PAIN MANAGEMENT WITH THE FENTANYL IONTOPHORETIC TRANSDERMAL SYSTEM
Abraham J1, Ogden K2, Wang Y1, Jones J1, The Medicines Company, Waltham, MA, USA, ICON, San Francisco, CA, USA, The Medicines Company, Parsippany, NJ, USA

PSY24 P9 pgA295 COMPARING THE ECONOMIC BURDEN OF VARIOUS DISEASES FROM A PAYER’S PERSPECTIVE IN CHINA
Wang BC1, Chen Y2, Furnback W1, Yang R1, Xie L1, Eisai Group, LLC, New York, NY, USA, Pfizer Investment Co. Ltd., Beijing, China, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin, China

PSY25 Q1 pgA296 TIMING OF FIRST-TIME USE OF BIOLOGICS AND HEALTHCARE COSTS AND UTILIZATION IN PSORIASIS
Feldman SR1, Herrera V1, Zhao Y1, Shi L1, Wake Forest University School of Medicine, Winston-Salem, NC, USA, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Novartis Pharmaceuticals, East Hanover, NJ, USA, Tulane University, New Orleans, LA, USA

PSY26 Q2 pgA296 COST-MINIMIZATION ANALYSIS OF INFlixIMAB VERSUS ADALIMUMAB IN THE TREATMENT OF CROHN’S DISEASE AND ULCERATIVE COLITIS
De Paula E, Blumer Vd, Trevizam YC, Asano EW, Medinsight - Decisions in Healthcare, NA, Brazil

PSY27 Q3 pgA296 ADHERENCE TO IRON CHELATION THERAPY AND ASSOCIATED HEALTHCARE RESOURCE UTILIZATION AND COSTS IN MEDICAID PATIENTS WITH THALASSEMIA
Vekeman F1, Sasane M1, Cheng WY2, Agnihotam RV2, Fortier J2, Duh MS3, Paley C2, Adams-Graves P2, Groupe d'analyse, Montreal, QC, Canada, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Analysis Group, Boston, MA, USA, Groupe d'analyse, Ltee, Montreal, QC, Canada, University of Tennessee, Memphis, TN, USA

PSY28 Q4 pgA296 PREVALENCE AND ECONOMIC BURDEN OF PRESCRIPTION OPIOID MISUSE AND ABUSE SYSTEMATIC REVIEW
Oderda G1, Lake J1, Rudell K1, Roland CL1, Masters E1, University of Utah, Salt Lake City, UT, USA, Pfizer Inc, Tadsworth, UK, Pfizer Inc, Durham, NC, USA, Pfizer Inc., New York, NY, USA

PSY29 Q5 pgA296 DEMOGRAPHIC DISTRIBUTION AND HEALTH CARE BURDEN OF PATIENTS DIAGNOSED WITH ANKYLOSING SPONDYLITIS IN THE U.S. MEDICARE POPULATION
Mao X1, Li L1, Shrestha S1, Baser O1, Yuce H1, Wang L1, University of Texas at Dallas and STATinMED Research, Plano, TX, USA, STATinMED Research, Plano, TX, USA, STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, City University of New York & STATinMED Research, New York, NY, USA

PSY30 Q6 pgA296 DIRECT HEALTHCARE COSTS OF OPIOID ABUSE IN PATIENTS PRESCRIBED IMMEDIATE RELEASE HYDROCODONE IN THE UNITED STATES
Michna E1, Chitinis A2, Paramore C2, Holly P3, Bell JA2, BenJoseph R1, Brigham and Women’s Hospital, Chestnut Hill, MA, USA, Evidera, Lexington, MA, USA, Purdue Pharma L.P., Stamford, CT, USA

PSY31 Q7 pgA297 COST PER ADDITIONAL RESPONDER ASSOCIATED WITH BIOLOGIC USE IN PSORIASIS
Foster S, Zhu B, Al Sawah S, Eli Lilly and Company, Indianapolis, IN, USA

PSY32 Q8 pgA297 EFFECT OF WEIGHT LOSS (WL) ON CONCOMITANT MEDICATION COSTS IN OBESE/OVERWEIGHT INDIVIDUALS WITH METABOLIC SYNDROME (METS) RECEIVING PHENTERMINE/TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER)
**PSY33** Q9 pgA297 PHARMACOTHERAPEUTIC AND ECONOMIC INDICATORS OF THE USE OF IMMUNOBIOLOGICALS DRUGS: ANALYSIS OF A RHEUMATIC PATIENT COHORT

Reis HP, Magalhaes DD, Albuquerque IM, Vieira JB, Sartori DP, Candido D, Alcantara AC, Ribeiro VD, Roldan AD, Filho NG, Rodrigues EX, UFC, Fortaleza, Brazil, UNIMED Fortaleza, Fortaleza, Brazil, Universidade Federal do Ceará, Fortaleza, Brazil

**PSY34** R1 pgA297 PROJECTING BENEFITS FROM WEIGHT LOSS IN OBESE POPULATIONS: A MICROSIMULATION APPROACH

Chen F, Iacobucci W, Su W, Dall T, IHS Inc., Washington, DC, USA, IHS Life Sciences, Washington, DC, USA

**PSY36** R2 pgA297 DEMONSTRATING THE COST EFFECTIVENESS OF MOVANTIK FOR THE TREATMENT OF OPIOID INDUCED CONSTIPATION IN PATIENTS WITH INADEQUATE RESPONSE TO LAXATIVES; A UK PERSPECTIVE


**PSY37** R3 pgA298 COST-EFFECTIVENESS ANALYSIS OF EX-VIVO EXPANDED AUTOLOGOUS CORNEAL EPITHELIAL CELLS CONTAINING STEM CELLS TO REPAIR THE DAMAGED OCULAR SURFACE IN PATIENTS WITH MODERATE TO SEVERE LIMBAL STEM CELL DEFICIENCY DUE TO OCULAR BURNS IN THE UK

Fordham R, Cimnata G, Madoni A, Magni T, Ardigo D, Pelosi D, Withe M, Sarnelli V, Delletto P, Domini B, University of East Anglia, Norwich, UK, Chiesi Farmaceutici Spa, Parma, Italy, Ernst & Young, Milano, Italy

**PSY38** R4 pgA298 COST-EFFECTIVENESS OF HOME-BASED FATIGUE SELF-MANAGEMENT INTERVENTION: A RANDOMIZED CONTROLLED TRIAL

Meng H, Friedberg F, University of South Florida, Tampa, FL, USA, Stony Brook University, Stony Brook, NY, USA

**PSY39** R5 pgA298 COST-EFFECTIVENESS OF RITUXIMAB VERSUS CALCINEURIN INHIBITORS FOR REFRACTORY MYASTHENIA GRAVIS

Georgieva M, Wheeler S, Howard Jr. JF, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

**PSY40** R6 pgA298 COST MINIMIZATION ANALYSIS OF EQUIPOTENT OPIOID ANALGESICS: NATIONWIDE ANALYSIS OF MEDICARE PART D STAND-ALONE PRESCRIPTION DRUG PLANS

Li H, Patel R, University of the Pacific, Stockton, CA, USA

**PSY41** R7 pgA298 FORECASTING THE UNITED STATES LIFETIME COST AND OUTCOMES OF IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS

Dilokthornsakul P, Campbell JD, University of Colorado Anschutz Medical Campus, Denver, CO, USA

**PSY42** R8 pgA298 COST-UTILITY ANALYSIS OF PAIN MEDICATIONS USED TO TREAT ADULT PATIENTS WITH CHRONIC BACK PAIN IN THE UNITED STATES

Shah D, Anupindi VR, Vaidya V, University of Toledo, Toledo, OH, USA

**PSY43** R9 pgA299 KIDNEY INVOLVEMENT IN TUBEROUS SCLEROSIS COMPLEX: THE IMPACT ON HEALTH CARE RESOURCE USE AND COSTS IN THE NETHERLANDS

Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Zonenberg BA, Groupe d'analyse, Montreal, QC, Canada, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Analysis Group, Boston, MA, USA, University Medical Center Utrecht, Utrecht, The Netherlands

**SYSTEMIC DISORDERS/CONDITIONS** - Patient-Reported Outcomes & Patient Preference Studies

**PSY44** S1 pgA299 CHARACTERISTICS OF COMBINATION PHARMACOTHERAPY IN PATIENTS WITH DIABETIC PAINFUL NEUROPATHY (DPN)

Kahan S, Karnawat S, George Washington University School of Public Health and Health Services, Washington, DC, USA, VIVUS, Inc, Mountain View, CA, USA

**PSY45** S2 pgA299 INITIAL IMPACT OF TELEPHARMACY ON SPECIALTY MEDICATION ADHERENCE

Fensterheim LE, Gunn JG, Pokuta KL, Straszewski A, Marks A, Catamaran, Chicago, IL, USA, Catamaran, Schaumburg, IL, USA

**PSY46** S3 pgA299 UNMET NEEDS AND TREATMENT PATTERNS IN LUPUS: RESULTS FROM AN ONLINE COMMUNITY

Wang VC, Hanger M, Vaughan T, Woyczynski M, Wicks P, PatientsLikeMe, Cambridge, MA, USA

**PSY47** S4 pgA299 ESTIMATING UTILITY VALUES FOR POLYCYTHEMIA VERA USING PATIENT-REPORTED OUTCOMES FROM THE RESPONSE TRIAL AND EXISTING MAPPING ALGORITHMS

Thompson M, Pepper AN, Côté I, Oliver N, Cornerstone Research Group, Burlington, ON, Canada, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Novartis Pharmaceuticals UK Limited, Frimley/Camberley, Surrey, UK

**PSY48** S5 pgA300 THE IMPACT OF INCREASING SEVERITY OF HEREDITARY HAEMOCHROMATOSIS ON HEALTH STATE UTILITY VALUES

de Graaff BL, Neil A, Sanderson K, Yee KC, Palmer A, University of Tasmania, Hobart, Australia
PSY49 S6 pgA300 IMPROVED HEALTH STATUS OF HAEMOPHILIA B PATIENTS TREATED WITH NONACOG BETA PEGOL, A NEW GLYCOPEGYLATED RECOMBINANT FIX PRODUCT WITH PROLONGED HALF-LIFE

Chowdary P1, Kearney S1, Yee DL1, Meunier J1, Slothuus U1, Hoxer CS2, Royal Free Hospital, London, UK, 1Children's Hospital and Clinics of Minnesota, Minneapolis, MN, USA, 2Texas Children's Hemophilia & Thrombosis Center, Houston, TX, USA, 3Mapi, Lyon, France, 4Novo Nordisk A/S, Søborg, Denmark

PSY50 S7 pgA300 USE OF INFlixIMAB WITHIN A PATIENT SUPPORT PROGRAM: POSITIVE PERCEPTION OF IV INFUSIONS FROM PATIENTS' PERSPECTIVE

Dyrcda P1, O'Reilly R2, Williamson M1, Dajnowiec D1, Jones J3, Borgaonkar M4, Siffedeen J5, Anger D5, Thompson M6, Janssen Inc., Toronto, ON, Canada, 1University of Toronto, Toronto, ON, Canada, 2Dalhousie University, Halifax, NS, Canada, 3Memorial University, St. John's, NF, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Cornerstone Research Group, Burlington, ON, Canada

PSY51 S8 pgA300 POTENTIAL PATIENT-REPORTED PREDICTORS OF OPENNESS TO AND PREFERENCE FOR BIOLOGIC THERAPY AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Goren A1, Teeple A2, Ingham M3, Kantar Health, New York, NY, USA, 4Janssen Scientific Affairs, LLC, Horsham, PA, USA

PSY52 S9 pgA300 IBRUTINIB FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): EVALUATING THE CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES AND DURABILITY OF RESPONSE IN A PHASE 2 STUDY

Ryle S1, Goy A2, Martin P3, Ramchandren R4, Alexeeva J5, Popat R6, Avivi I7, Advani R8, Le Gouill S9, Horowitz N10, Yuan Z11, Kranenburg B12, Zhuang SH13, Deraedt W14, Rizo A15, Wildsgtt M16, Wang M17, Derriford Hospital, Plymouth, UK, 1John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA, 2Weill Cornell Medical College, New York, NY, USA, 3Wayne State University Hudson-Webber Cancer Research Center, Detroit, MI, USA, 4Federal Medical Research Center, St. Petersburg, Russia, 5University College London Hospitals NHS Foundation Trust, London, UK, 6Tel Aviv Medical Center, Tel Aviv, Israel, 7Stanford Cancer Institute, Palo Alto, CA, USA, 8Service d’hémato-logie clinique Université de Nantes, Nantes, France, 9Rambam Health Care Campus, Haifa, Israel, 10Janssen Research & Development, LLC, Raritan, NJ, USA, 11Janssen Biologics B.V., Leiden, The Netherlands, 12Janssen Research & Development, LLC, Beersse, Belgium, 13The University of Texas MD Anderson Cancer Center, Houston, TX, USA

PSY53 T1 pgA301 CORRELATION BETWEEN PAIN CATASTROPHIZING SCALE AND DISEASE CHARACTERISTICS IN CHRONIC LOW BACK PATIENTS

Lavudiva S1, Bansal D2, Ghai B3, Gudala K4, National Institute of Pharmaceutical Educational and Research, Mohali, India, 5National Institute of Pharmaceutical Education and Research, Mohali, India, 6Postgraduate Institute Medical Education and Research, Chandigarh, India

PSY54 T2 pgA301 A REVIEW OF PATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS WITH CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)

Ogunsanya M1, Kalb S2, Chen S3, The University of Texas at Austin, Austin, TX, USA, 4Biogen Idec, Cambridge, MA, USA

PSY55 T3 pgA301 SHARED DECISION MAKING AMONG PATIENTS WITH AUTOIMMUNE CONDITIONS INITIATING BIOLOGIC THERAPY: INITIAL FINDINGS

Lofland J1, Johnson PT2, Watkins A2, White JC3, 1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Optum, Eden Prairie, MN, USA

PSY56 T4 pgA301 SYSTEMATIC REVIEW OF THE PATTERNS OF USE, CHARACTERISTICS, AND QUALITY OF PATIENT REPORTED OUTCOME MEASURES IN CELIAC DISEASE

Canestaro WJ, Edwards TC, Patrick DL, University of Washington, Seattle, WA, USA

PSY57 T5 pgA301 PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH TYPE 1 MYOTONIC DYSTROPHY TYPE 1 – A SYSTEMATIC LITERATURE REVIEW

Ogunsanya M1, Kalb S2, Yeh W3, The University of Texas at Austin, Austin, TX, USA, 4Biogen Idec, Cambridge, MA, USA

PSY58 T6 pgA301 PAIN FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE (P-FIQ): AN ASSESSMENT OF RELIABILITY OF FIVE PATIENT REPORTED OUTCOME (PRO) INSTRUMENTS IN ADULT PEOPLE WITH HEMOPHILIA (PWH)

Kempton CL1, Wang M2, Recht M3, Neff A4, Shapiro AD5, Buckner T6, Kulkarni R7, Nugent D8, Batt K9, Wisniewski T10, Cooper DL10, 1Emory University School of Medicine, Atlanta, GA, USA, 2Children’s Hospital Colorado, Aurora, CO, USA, 3Oregon Hemophilia Treatment Center, Portland, OR, USA, 4Vanderbilt University Medical Center, Nashville, TN, USA, 5Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA, 6University of Colorado School of Medicine, Aurora, CO, USA, 7Michigan State University, East Lansing, MI, USA, 8Children's Hospital of Orange County and UC Irvine Department of Pediatrics, Orange, CA, USA, 9Wake Forest School of Medicine, Winston-Salem, NC, USA, 10Novo Nordisk Inc., Plainsboro, NJ, USA

PSY59 T7 pgA302 MEASUREMENT PROPERTIES OF WEB BASED LUPUSPRO, A DISEASE TARGETED OUTCOME TOOL, AMONG ITALIAN PATIENTS WITH LUPUS

Jolly M1, Mazzoni D2, Cicognani E3, 1Rush University Medical Center, Chicago, IL, USA, 2University of Bologna, Bologna, Italy

PSY60 T8 pgA302 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR SICKLE CELL DISEASE PATIENTS
TREATED WITH CHEMOTHERAPY-FREE ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A PILOT STUDY
Jalundhwala YJ, Saraf SL, Rondelli D, Law EH, Pickard AS, University of Illinois at Chicago, Chicago, IL, USA

SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies

PSY61 T9 pgA302 CHARACTERISTICS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) CURRENTLY EXPERIENCING FLARES IN CLINICAL PRACTICE SETTINGS IN EUROPE (EU)
Narayanan S1, Hutings R2, Lu Y3, Ipsos Healthcare, columibia, MD, USA, 4Ipsos Healthcare, London, UK

PSY62 U1 pgA302 TRENDS IN APPROVALS OF NEW DRUGS WITH ORPHAN DESIGNATION IN THE US (1983-2014)
Alhawwashi ST1, Alsahhari AM1, Alsahahi SM1, Alasmar MS1, Seoane-Vazquez E2, Rodriguez-Monguio R3, Szeinbach SL4, Massachusetts college of pharmacy and health science, Boston, MA, USA, 5MCPHS University, Boston, MA, USA, 6University of Massachusetts, Amherst, Amherst, MA, USA, 7The Ohio State University, Columbus, OH, USA

PSY63 U2 pgA302 DETERMINING PATTERNS OF OPIOID MISUSE AND MISPREScribing IN SOUTH CAROLINA
Qureshi Z1, Ball S2, Horner R1, Kreiner P3, Lopez-Defede A1, Probst J1, Bennett C1, University of South Carolina, Columbia, SC, USA, 2South Carolina College of Pharmacy, Charleston, SC, USA, 3Brandeis University, Waltham, MA, USA, 4University of South Carolina, COLUMBIA, SC, USA, 5University of South Carolina College of Pharmacy, Columbia, SC, USA

PSY64 U3 pgA303 TREATMENT PATTERNS AMONG CHRONIC USERS OF IMMEDIATE-RELEASE OXYCODONE INITIATING TREATMENT WITH EXTENDED-RELEASE OPIOIDS
Pergolizzi JV1, Kirson NY2, Bell J3, Jones C4, Mantovanielli F5, Cummings AG6, Birnbaum HG7, Ben-Joseph R8, Naples Anesthesia and Pain Associates, INC., Bonita Springs, FL, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Purdue Pharma L.P., Stamford, CT, USA, 4Analysis Group, Inc., Boston, MA, USA, 5Analysis Group, Boston, MA, USA

PSY65 U4 pgA303 CROSS-STATE COMPARISON OF MEDICAID ANTI-OBESITY MEDICATION COVERAGE: 1999-2013
Xia Y1, Kelton CM, Heaton PC, Guo JJ, University of Cincinnati, Cincinnati, OH, USA

PSY66 U5 pgA303 HYDROCODONE: A REVIEW OF THE LITERATURE
Hattfield MD1, Fleming ML, University of Houston, Houston, TX, USA

PSY67 U6 pgA303 ESTIMATION OF MEDICAL EXPENDITURE ASSOCIATED WITH OPIOIDS USAGE IN CHRONIC NON CANCER PAIN: A CROSS-SECTIONAL STUDY BASED ON MEDICAL EXPENDITURE SURVEY AND PANEL DATA
Zhang Y1, Dana Farber Cancer Institution, boston, MA, USA

PSY68 U7 pgA303 DOSING PATTERN ANALYSIS FOR BIOLOGICS IN THE TREATMENT OF PSORIASIS IN CANADA: INDICATION-SPECIFIC INFORMATION RETRIEVED FROM ADMINISTRATIVE CLAIMS DATABASE
Gregory V1, Liu N2, Robertson C3, Gerega S4, Barbeau M1, Budy L5, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2IMS Health, Mississauga, ON, Canada, 3IMS Health, Kirkland, QC, Canada, 4Université de Montréal, Montreal, QC, Canada

PSY69 V1 pgA304 EFFECT OF FLORIDA'S PRESCRIPTION MONITORING PROGRAM AND PILL-MILL LAWS ON OPIOID PRESCRIBING AND UTILIZATION
Daubresse M1, Rutkow L2, Chang H3, Stuart E1, Webster D1, Alexander GC2, Johns Hopkins School of Public Health, Baltimore, MD, USA, 2Johns Hopkins School of Public Health, Center for Drug Safety and Effectiveness, Baltimore, MD, USA

PSY70 V2 pgA304 THE CHANGING COSTS OF CARING FOR HEMOPHILIA PATIENTS IN THE U.S.: INSURERS' AND PATIENTS' PERSPECTIVES
Eldar-Lissai A1, Hou Q, Krishnan S, Biogen Idec, Cambridge, MA, USA

PSY71 V3 pgA304 INCREASED LENGTH OF STAY FOR OBESE PATIENTS BY CHRONIC DISEASE
Hoshen MB1, Leventer-Roberts M, Balicer R, Clalit Research Institute, Tel Aviv, Israel

PSY72 V4 pgA304 THE AVAILABILITY AND EXPENDITURE OF ORPHAN MEDICINES IN POLAND
Sukiowska G1, Jagodzińska-Kalinowska K, Matusewicz W, Agency for Health Technology Assessment and Tariff System, Warsaw, Poland

PSY73 V5 pgA304 BARIATRIC SURGERY IN THE BRAZILIAN HEALTH CARE SYSTEM: RESOURCES UTILIZATION
Junqueira Junior SM1, Andrade PC1, Cabra HA2, Luque A1, Oliveira FM3, Johnson & Johnson Medical Brazil, Sao Paulo, Brazil, 2Johnson & Johnson Medical, Mexico, D.F., Mexico, 3Johnson & Johnson Medical Brazil, São Paulo, Brazil

PSY74 V6 pgA304 CANADIAN RETROSPECTIVE CLAIMS DATA ANALYSIS OF BIOLOGICS SWITCHING AND RETENTION PATTERNS IN PSORIASIS PATIENTS
Millson B1, Poulin-Costello M2, Garces K2, IMS Brogan, Kirkland, QC, Canada, 2Amgen Canada Inc., Mississauga, ON, Canada

PSY75 V7 pgA305 COMPARISON OF ULTRA ORPHAN AND CANCER DRUG PRICING IN THE US AND THE UK
Kumar S1, Angarwai S2, Topaloglu H3, 1GLOBAL ACCESS Monitor, Bethesda, MD, USA, 2NOVEL Health
PSY76 W1 pgA305 ORPHAN DRUG DESIGNATION: A COMPARISON OF POLICIES, PROCESSES AND RESULTS FROM THE US AND THE EU
Shields GE1, Arranhado Neves AC1, Bajpai SK2, BresMed, Sheffield, UK, 2Institute of Pharmaceutical Management, Yardley, PA, USA

PSY77 W2 pgA305 TIMING OF EU5 & US ORPHAN DRUG APPROvals AND PRMA BETWEEN 2009 AND 2013
Mycka J1, Dellamano R2, Lobb W3, Dalal N4, Pereira E5, Dellamano L6, Sagaydachnaya O5, Lue J5, 1Medical Marketing Economics LLC (MME), Montclair, NJ, USA, 2ValueVector, Milan, Italy

PSY78 W3 pgA305 DRIVERS OF HEALTHCARE RESOURCE UTILIZATION AND FACTORS ASSOCIATED WITH INCREASED RESOURCE USE IN PATIENTS WITH FIBROMYALGIA: AN EVALUATION USING ELECTRONIC MEDICAL RECORDS
Margolis J1, Masters ET2, Cappelleri JC3, Smith DM4, Faulkner ST5, Thompson E5, 1Truven Health Analytics, Bala Cynwyd, PA, USA, 2Pfizer Inc., New York, NY, USA, 3Pfizer Inc., Groton, CT, USA, 4Truven Health Analytics, Bethesda, MD, USA, 5Pfizer Inc., Edwardsville, IL, USA

PSY79 W4 pgA305 SUGAR-SWEETENED BEVERAGES CONSUMPTION AND PRICE SENSITIVITY AMONG BRAZILIAN ADULTS: IMPLICATIONS FOR OBESITY POLICIES
Cardoso LB, UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL, PORTO ALEGRE, Brazil

PSY80 W5 pgA305 WHY ASK IF YOU KNOW? ACMG’S POTENTIAL ERRORS IN MAKING NEWBORN SCREENING (NBS) RECOMMENDATIONS FROM USING SURVEYED OPINIONS FOR INCIDENCE SCORING WHEN ACTUAL DATA ARE AVAILABLE
Algarni M, Almutairi H, Rittenhouse B, MCPHS University, Boston, MA, USA

PSY81 W6 pgA306 HOW MUCH IS NICE REALLY PREPARED TO PAY FOR ORPHAN AND END-OF-LIFE DRUGS?
Griffiths EA, Martin RL, HERON Commercialization, London, UK

PSY82 W7 pgA306 HOW INFLUENTIAL ARE PATIENT AND PROFESSIONAL GROUP SUBMISSIONS ON REIMBURSEMENT DECISIONS FOR EUROPEAN MEDICINES AGENCY ORPHAN DRUGS?
Chang R, Versoza L, Jaksa A, Ho Y, Context Matters, New York, NY, USA

PSY83 W8 pgA306 TREATMENT OF OBESITY: PHARMACOTHERAPY TRENDS IN THE UNITED STATES FROM 1999 TO 2010
Xia Y, Kelton CM, Heaton PC, Guo JJ, University of Cincinnati, Cincinnati, OH, USA

PSY84 X1 pgA306 IMPLEMENTATION OF A STATEWIDE OPIATE PRESCRIBING POLICY IS NOT ASSOCIATED WITH A SIGNIFICANT DECREASE IN OPIATE PRESCRIPTIONS FROM THE EMERGENCY DEPARTMENT
McGhee JD, Bounds RB, Papas MA, Coletti C, Christiana Care Health System, Newark, DE, USA

PSY85 X2 pgA306 ASSESSING THE IMPACT OF VARYING THRESHOLD CRITERIA FOR OPIOID OVERUTILIZATION
Durkin M1, Moll K1, Pasquale MK2, Amos T2, Null KD2, 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Comprehensive Health Insights, Louisville, KY, USA
Looking for poster presentations online?

The ISPOR Scientific Presentations Database is a searchable database of over 31,500 research papers presented at ISPOR meetings since 1998. The database is searchable by disease, topic, meeting, key word and author. To access the database, go to www.ispor.org and click the purple “Scientific Presentations” tab.